
















The challenge with todays microarray experiments is to infer biological conclusions
from them. There are two crucial difficulties to be surmounted in this challenge:(1)
A lack of suitable biological repository that can be easily integrated into computational
algorithms. (2) Contemporary algorithms used to analyze microarray data are unable to
draw consistent biological results from diverse datasets of the same disease.
To deal with the first difficulty, we believe a core database that unifies available
biological repositories is important. Towards this end, we create a unified biological
database from three popular biological repositories (KEGG, Ingenuity and Wikipath-
ways). This database provides computer scientists the flexibility of easily integrating
biological information using simple API calls or SQL queries.
To deal with the second difficulty of deriving consistent biological results from the
experiments, we first conceptualize the notion of “subnetworks”, which refers to a
connected portion in a biological pathway. Then we propose a method that identifies
subnetworks that are consistently expressed by patients of he same disease phenotype.
We test our technique on independent datasets of several diseases, including ALL,
DMD and lung cancer. For each of these diseases, we obtain two independent microarray
datasets produced by distinct labs on distinct platforms. In each case, our technique
consistently produces overlapping lists of significant nontrivial subnetworks from two
independent sets of microarray data. The gene-level agreement of these significant
subnetworks is between 66.67% to 91.87%. In contrast, when the same pairs of
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microarray datasets were analysed using GSEA and t-test, this percentage fell between
37% to 55.75% (GSEA) and between 2.55% to 19.23% (t-test). Furthermore, the genes
selected using GSEA and t-test do not form subnetworks of substantial size. Thus
it is more probable that the subnetworks selected by our technique can provide the
researcher with more descriptive information on the portions of the pathway which
actually associates with the disease.
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CHAPTER 1
Introduction
This dissertation is concerned with making consistent biological inferences from mi-
croarray experiments and prior biological information. Although technological limita-
tions in such experiments have been considerably reduced over the past decade, there
still exists challenges in providing proper diagnosis and understanding, part of the
challenges arising from our incomplete knowledge of the functions of biological systems
(Berger and Iyengar, 2009). This dissertation first argues that contemporary biolog-
ical repositories seriously limit the availability of such information to computational
methods. Such limitations will be all the more evident as microarray experiments
evolve in size and complexity. This dissertation next advocates incorporating biological
information into algorithms to support microarray analysis, and demonstrates this
concept with a working algorithm.
1.1 Motivation
The challenge with todays microarray experiments is to be able to infer biological conclu-
sions from them. This challenge has traditionally been tackled as a pure computational
problem. Hence solutions (Choe et al., 2005; Tusher et al., 2001) generally entail running
experimental data through algorithms and selecting statistically significant genes. This
approach, albeit mathematically sound, ignores the biological motivations behind the
microarray experiment. Such an analysis usually leaves the investigator with a large
list of genes and information correlated mathematically but unwieldy for biological
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inferences. In addition, most of these techniques strongly rely on an arbitrary p-value
cutoff used to select differentially expressed genes (Sivachenko et al., 2005).
To obtain results both of high accuracy as well as biological relevance, there is
therefore a need to incorporate insights (Pavlidis et al., 2002; Subramanian et al.,
2005) from additional biological repositories into our investigations. This allows us
to complement the mathematical results with biological background, providing the
clinician with relevant biological results.
However even these contemporary techniques (which integrate biological information)
share a number of limitations. First, many of these techniques rely only gene sets
present within biological processes and pathways, ignoring the different intricate
connections and topology within pathways. For example (Tarca et al., 2008) showed
that such topological details can be extremely crucial. In particular, the authors stated
that within the insulin pathway, if the insulin receptor (INSR) is not present, the entire
pathway will be shut off. Hence in the scenario where some of the genes appear to be
differentially expressed within the insulin pathway but INSR is not present, this might
mean that the genes differentially expressed are not connected to one another and might
not affect the pathway significantly.
Some algorithms (Liu et al., 2007) utilize global protein connections which ignore the
fact that majority of proteins participate in multi-domain processes (Liu et al., 2009) and
such global process may not translate similarly locally to smaller pathways (Sivachenko
et al., 2007).
Lastly, these algorithms only consider individual pathways or gene sets as a whole.
This ignores the fact that many times, only a portion of a gene network might be
significantly perturbed (Sohler et al., 2000) and this portion might be ignored if its
proportion within the network is not large enough. This happens especially when the
gene set is extremely large.
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1.2 Goal of Thesis
The goal of this thesis is to make consistent biological inferences from microarray
experiments and prior biological information. Intuitively, the thesis appears viable for
the following reasons:
• The biological repository created is currently being used in a research environment
for tasks such as extracting genes or gene relationships from pathways.
• The designed algorithm has been tested with four different diseases (eight unique
datasets, two datasets for each disease) and we are able to find consistent biological
information independently derived from the dataset pair from each disease.
These observations lead directly to the thesis statement:
Incorporating accurate and detailed biological information can
improve the consistency and reproducibility of biological inferences
for similar diseases across datasets.
1.3 Contributions
Our thesis has the following two main contributions:
1. Creation of an aggregated biological pathway database, providing the database
with a unified access method (through API calls) and standardizing data formats.
This aggregation of data reduces the scenario of conflicting or missing data from
solitary pathway databases. The unification of access methods and data formats
allows easy access to researchers who wish to access data from diverse databases.
2. Conception and development of a technique for microarray analysis which provides
descriptive biological analysis to microarray data. Results from our microarray
technique provides the researcher not only with the genes or pathways that are
differentially expressed, it directly gives a clear representation of the intricate
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relationship between such differentially expressed genes within their biological
pathways. In addition, results from our techniques have been verified empirically,
showing consistent results across different databases of the same disease. This
gives us additional confidence that our technique is able to identify relevant
pathways because they are consistently significant across diverse datasets.
1.4 Publications
We had the honor of working with diverse research groups during the course of this
dissertation. These collaborative efforts have been significant contributions to this
thesis and are listed as publications below. Publication I has been heavily expounded in
Chapters 2 and 3. Much of the work in Chapters 3, 4 and 5 revolves around Publication
III while Publication IV contains work from Chapters 6 and 7. Publication II involves
a real life clinical example where we employed some microarray analysis on patients
suffering from NPC (Nasopharyngeal Cancer) (we mention this briefly in Chapter 2).
Finally Publication V stands out independently as a theoretical framework that could be
employed in the future for subnetwork analysis.
I Donny Soh, Difeng Dong, Yike Guo, Limsoon Wong. Enabling More Sophisticated
Gene Expression Analysis for Understanding Diseases and Optimizing Treat-
ments. ACM SIGKDD Explorations, 9(1):3-14, June 2007.
II Wen-Son Hsieh, Ross Soo, Bee-Keow Peh, Thomas Loh, Difeng Dong, Donny
Soh, Limsoon Wong, Simon Green, Judy Chiao, Chun-Ying Cui, Yoke-Fong Lai,
Soo-Chin Lee, Benjamin Mow, Richie Soong, Manuel Salto-Tellez, Boon-Cher
Goh. Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle
Modulator, in Undifferentiated Nasopharyngeal Cancer. Clinical Cancer Research,
15(4):1435–1442, February 2009.
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III Donny Soh, Difeng Dong, Yike Guo, Limsoon Wong. Consistency, Comprehensive-
ness, and Compatibility of Pathway Databases. BMC Bioinformatics, Vol. 11, No.
1. (2010), 449.
IV Donny Soh, Difeng Dong, Yike Guo, Limsoon Wong. Finding Consistent Disease
Subnetwork Across Datasets. Manuscript.
V Jinyan Li, Haiquan Li, Donny Soh, Limsoon Wong: A Correspondence Between
Maximal Complete Bipartite Subgraphs and Closed Patterns. PKDD 2005: 146-
156.
1.5 Organization of the Thesis
This thesis focuses on developing techniques whereby consistent biological analysis can
be made. To achieve this, we subdivide the task into two smaller portions. (1) the
modeling, implementation and realization of a unified biological database and (2) a
technique that uses this unified database to draw consistent biological conclusions from
independent datasets. This thesis is organized as:
• Background: Algorithm
Microarrays have made it technologically feasible for researchers to measure
the expression levels of thousands of genes simultaneously. Through microarray
analysis techniques, researchers are able to understand the behavior of individual
genes. This chapter concerns itself with scrutinizing some popular analysis
techniques often employed to analyze microarrays and review their ability of
providing consistent and descriptive biological results to microarray experiments.
We conclude the chapter by suggesting that contemporary methods are unable
to generate consistent and descriptive biological results because (1) they place
a greater emphasis on computational models rather than descriptive biological
analysis and (2) whatever biological information used is either too fine (individual
genes) or too coarse (entire gene sets) for use in biological descriptive reasonings.
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• Background: Pathway API
One of the critical assumptions underlying microarray techniques which inte-
grates biological information (biological pathways) as a priori data into their
computational analysis is the availability of a collection of well-curated biological
repositories (for example, Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Kanehisa and Goto, 2000), Ingenuity (Ingenuity, 1998)). We review several
representative biological databases and analyze their suitability to be used as a
priori biological information for computational microarray analysis. Our survey
findings conclude that contemporary biological databases are very diverse, lacking
in complete data and not suitable for integration into computational algorithms.
These reasons lead us to create our own unified database cache and its API for
easy integration into computational algorithms.
• Pathway API — Methods
Because of the lack of consistency, comprehensivity and compatibility of current
databases (shown in the previous chapter), we decided to create our own unified
database cache and its API. This chapter explains the technical challenges and
techniques we employed in designing and creating our own biological repository.
We pay special attention to achieving data comprehensiveness by integrating
biological data from three representative biological repositories, achieving data
consistency through the standardization of nomenclature, data formats and lastly
compatibility through the easy data accessibility of a web http API.
• Pathway API — Evaluation
This chapter evaluates our database (both quantitatively and qualitatively) to
ensure that it is consistent, comprehensive and compatible for integration into com-
putational microarray algorithms. Quantitatively we show that, as we expected,
there is a low level of gene and gene pairwise consistency among the three different
biological databases (KEGG, Ingenuity, Wikipatways). Qualitatively, because we
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(1) unified pathway data from three independent biological sources, (2) created
consistent data access methods and formats, and (3) standardized nomenclature
such as gene references and pathway key features, researchers will be able to
access complete information (from different databases) easier by using a single
access method (PathwayAPI) and standardized nomenclature.
• Disease and Drug-Response Pathway Identification — Algorithm
Here we demonstrate the different decision making steps taken to ensure that
the results obtained from our technique will provide proper biological analysis
to microarray experiments. We first explain how we create the foundation to
allow biologically descriptive results by deciding on a proper level of granularity
required within the biological pathways of the unified database. Following which
we explain how we arrange genes into their respective pathway components to
take advantage of the gene-gene relationships within pathways. This is further
substantiated with an explanation of statistical testing (which is required to test
for significant pathway components). Finally, these are strung together with a
detailed explanation and example of our algorithm.
• Disease and Drug-Response Pathway Identification — Results
We compare our technique with several popular methods of microarray analysis
such as SAM (Tusher et al., 2001), t-test (Cui et al., 2005) and GSEA (Subramanian
et al., 2005) in this chapter. This comparison is made on four different disease
types and eight different datasets (Leukemia (Armstrong et al., 2002; Golub et al.,
1999), Leukemia Subtypes (Ross et al., 2004; Yeoh et al., 2002), DMD (Haslett
et al., 2002; Pescatori et al., 2007), Lung Cancer (Bhattacharjee et al., 2001; Garber
et al., 2001)).
We show that our technique generates significant subnetworks and genes that
are more consistent across datasets as compared to the other methods (GSEA, t-
test and SAM). The large size of subnetworks which we generate indicates that
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these subnetworks are more biologically significant (less likely to be spurious).
To validate our results, we show that most of our genes from the generated
subnetworks have also been considered significant by the t-test. In addition, we
have chosen two sample subnetworks and validated them with references from
biological literature. This shows that our algorithm is capable of generating
descriptive biologically conclusions.






Microarrays have made it technologically feasible for researchers to measure the ex-
pression levels of thousands of genes simultaneously. Through microarray analysis
techniques, researchers are able to understand the behaviour of individual genes and
widely adopted in many areas to detect changes in gene activity. Traditionally,
microarray data is analysed via individual genes, identifying changes in specific genes
against certain conditions. While this approach works well in identifying genes which
react the most significantly, it neglects the underlying biological mechanisms causing
such gene activity changes. Such biological mechanisms are the result of interactions
between multiple genes within a biological pathway. Hence the challenge with todays
microarray analysis is being able to infer such biological conclusions consistently. Here
we scrutinise some popular analysis techniques often employed to analyse microarrays
and review their ability of providing consistent and descriptive biological results to
microarray experiments.
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Conclusions
Our literature review seems to suggest that contemporary methods are unable to generate
consistent and descriptive biological results because (1) they place a greater emphasis
on computational models rather than descriptive biological analysis and (2) biological
information used is either too fine (individual genes) or too coarse (entire gene sets)
for use in biological descriptive reasonings. For ease of discussion, we have segregated
contemporary techniques into three different categories (based on their methodology): (1)
individual gene testing, (2) gene pathway testing and (3) gene class testing.
Techniques (Tusher et al., 2001) which belong to our first category of algorithms
(individual genes testing) often ignore biological motivations behind the microarray
experiment, usually leaving the investigator with unwieldy gene lists which makes it
difficult to draw biological conclusions. Gene pathway testing techniques attempt to
organise and infer genetic networks from microarray data. This process is challenging
because of the large number of samples as compared to patients making such inferences
suffer from a high incidence of false positives, creating biological pathways with limited
biological foundations.
The last category of techniques, gene class testing techniques have attempted to
alleviate these issues by integrating biological information within the analysis. Yet most
of these techniques merely integrate biological information on a level of granularity which
is too coarse for descriptive biological inferences (Sivachenko et al., 2007; Subramanian
et al., 2005). For example, the output of these algorithms is normally a set of gene groups
(pre-divided based on their functions) and selected based on the overexpression of its
individual genes. This manner of selecting overexpressed pathways ignores the presence
of intricate connections and topology. Such rigidity also causes these algorithms to be
unable to detect overexpressed gene groups if they occur only within a portion of the gene
group.
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2.1 Introduction
Humans have tens of thousands of genes, and the development of DNA microarrays by
Patrick O. Brown, Joseph DeRisi, David Botstein, and colleagues in the mid-1990s made
it possible to examine the expression of thousands of genes at once (Hoopes, 2008). Since
then, microarray technology has evolved and we are now able to embed the entire human
genome unto a single microarray.
In a similar fashion, many techniques for making microarray analysis have emerged.
From this wealth of techniques for identifying significant differential gene expression,
we categorise them into three approaches; viz., individual genes, gene pathways and
gene classes approaches. In this chapter we present the approaches below:
1. Individual Gene Testing
These techniques highlighted in (Baldi and Long, 2001; Cheng and Church,
2000; Golub et al., 1999; Tusher et al., 2001) search for individual genes that
are differentially expressed. Traditionally, this approach consists of running
the experimental values either through statistical clustering or probabilistic
techniques, such as the fold change, t-test and Significance Analysis of Microarrays
(SAM) (Tusher et al., 2001). The SAM test is currently the most prevalent test
for testing of differential expressed genes within microarrays. The output of such
algorithms is a list of genes that are deemed differentially expressed.
2. Gene Pathway Testing
Methods of this genre attempt to infer biological information from data without
using pre-existing biological information. Bayesian learning (Friedman et al.,
2000) and Boolean network learning (Lähdesmäki et al., 2006) are representatives
of this approach. In this approach, the researcher obtains a set of connected
gene networks inferred solely from the gene expression data. While possible
pathway relationships can be obtained from such algorithms, it is more probable
that false positives – relationships which correlates statistically but have zero
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biological relevance – might be present. This refers to Type I (false positive)
errors. It happens when the expression level of totally unrelated genes display
high correlation with each other. Such spurious correlations occur mainly due to
the large number of genes (relative to the number of patient samples available for
analysis) that are being tested.
3. Gene Class Testing
These techniques test how gene classes behave as a whole. These techniques either
pre-process or post-process their information with existing biological background
knowledge to guide their analysis of the microarray data. Examples include
over-representation analysis (ORA) (Khatri and Draghici, 2005), Functional Class
Scoring (FCS) (Goeman et al., 2004), GSEA (Subramanian et al., 2005), GNEA
(Liu et al., 2007) and ErmineJ (Pavlidis et al., 2004b). Results from such methods
are normally a list of pathways or gene groups that are differentially expressed
according to the algorithms.
The commonly acknowledged challenge of these techniques is obtaining replicable
results. For instance, in differentially expressed gene discovery, there should be a
substantial overlap in the gene lists from different datasets of the same disease. This is
inferred from the premise that similar underlying conditions cause the onset of certain
diseases. However it has been shown that there is little concurrence among such gene
lists (Ein-Dor et al., 2005; Michiels et al., 2005; Zhang et al., 2009).
For example, (Zhang et al., 2009) demonstrated this inconsistency using SAM. For a
pair of datasets involving prostate cancer (Lapointe et al., 2004; Singh et al., 2002), he
calculated the percentage overlap of differentially expressed genes between them. The
top 10 genes had a percentage overlap of 30% while the top 100 genes had a percentage
overlap of 15%. The same calculations were repeated for lung cancer (Bhattacharjee
et al., 2001; Garber et al., 2001) and DMD (Haslett et al., 2002; Pescatori et al., 2007)
datasets, yielding similar low percentages.
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In addition, the functional gene lists, pathways or classes determined by such methods
do not provide sufficient descriptive information about the interplay and relationship
of genes (Soh et al., 2007). Hence the generated hypotheses are usually too general,
rendering them ineffective in guiding further research and treatment (Dong et al., 2009).
The remainder of this section explores the individual algorithms from the three
classes in greater detail.
2.2 Individual Gene Testing
Many methods exist for the identification of differentially expressed genes between
conditions. The interested reader can refer to (Allison et al., 2006; Madeira and Oliveira,
2004) for a large range of different techniques. Yet despite such a large plethora of
methods, biologists show a particular affinity for the two earliest approaches: fold
change (FC) and t-statistics. Their pervasiveness can be largely attributed to their
simplicity. Here we provide details of how the FC, modified FC, t-test, modified t-
test algorithms function. We will also provide details on SAM, one of the popular
contemporary algorithms for finding differentially expressed genes from microarray






There are two definitions of fold change in literature. The standard formula for
fold change is simply the number of times the expression level of a gene has in-
creased/decreased by (Tusher et al., 2001). It is given as follow:





where FCratioi is the fold change for gene i, xi and yi are the raw expression values
of the gene i in the control and treatment samples respectively. The second definition
defines fold change from a difference in expression values point of view (Choe et al.,
2005). The formula is:
FCdiffi = xi − yi (2.2)
It is noted that these two forms of fold change analyse slightly different forms
of changes. The FCratioi emphasises more on percentage changes whereas FCdiffi
emphasises absolute changes. The usage of either metrics will depend largely on the
data. In general, if the data has extremely low values, the latter formula might be more
useful because a small increase in the absolute raw value might indicate too large a
percentage increase. Conversely, if the data has a good range of values, using the former
one would seem relevant because it would be able to show us the significance of the
change in value.
2.2.2 t-test
There are three popular variants of the statistical t-test generally used in microarray





where Ti refers to the t-statistic, xˆi and yˆi refers to the mean log2 expression of genes
i in the control and treatment respectively. si thus refers to the standard error of these
replicates for gene i.
Chapter 2. Background Study on Microarray Analysis 15
However we find that such a calculation will yield a large variance for the values
for Ti. This is especially so if the values of the expression values are very small. This
is exacerbated due to the large number of genes compared to the small sample size.
Hence to ensure that the variance of Ti is independent of the gene expression, a small
positive constant is usually added to si. This is the technique used in the SAM algorithm





The last variant of the t-test involved tweaking the value of si, a technique known as





where s is the predicted variance of Ti based on all genes in the array and si is the
estimated variance of Ti based only on that single gene. Thus when B is equal to 0, it
will be the standard t-test statistic. Using this weighted combination of variance allows
information to be borrowed across genes.
2.2.3 Significance Analysis of Microarrays (SAM)
The different variants of the t-tests above provide a t-score to test the probability of that
gene being significant by coincidence. For instance, if we assign a p-value threshold of
0.05, all genes with a p-value of less than 0.05 will have their null hypothesis rejected.
This means that these genes will be declared as significant. The value of 0.05 means
that these genes have a 5% chance of being a false positive, known also as a Type I error.
Seen in this light, the t-test basically argues that because the probability of a Type I
error happening by chance is so low, the experiment has confidence that the event did
not occur by coincidence. Indeed, a p-value of 0.01 or even 0.05 is very suitable for such
usage in normal circumstances. However, in the context of microarray experiments,
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because we are doing multiple hypothesis testing of each gene within the microarray
experiment, we would probably be doing the hypothesis test 10,000 times (once for each
gene). Using a p-value cutoff of 0.01, it would mean that we are expected to get 100 Type
I errors / false positives, which would probably be too large a number to ignore.
This issue with the t-test leads to the development of Significance Analysis of
Microarrays, or SAM (Tusher et al., 2001), where genes are tested based on the change
in gene expression relative to the standard deviation of repeated measurements for that
gene and genes greater than a certain threshold are deemed to be significant. We will
describe how the number of Type I errors can be controlled using a technique known as
False Discovery Rate (FDR) (Benjamini and Yekutieli, 2001).






where x¯I(i) and x¯II(i) are the average levels of the expression values in Phenotypes
I and II respectively for gene i. The term s(i) in the denominator is known as the
gene-specific scatter and the term so is a positive constant to prevent genes whose
expression is near zero (and hence unreliable) from having large scores d(i). The








where M refers to the total number of patients in phenotype I, N refers to the total
number of patients in phenotype II and a = (1/m+1/n)/(m+n− 2). ∑Mm and∑Nn
are thus the summation of the calculations in phenotypes I and II respectively.
2. We calculate the value of the relative difference d(i) for all genes p in the microarray
experiment and order these statistics according to the magnitude of the d(i) values
such that dˆ(1) was the largest relative difference, dˆ(2) was the second largest
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relative difference, and dˆ(i) was the ith largest relative difference. This is shown
by the equation below in Equation 2.8
dˆ(1) < dˆ(2) < ... < dˆ(p) (2.8)
3. Next, we generated a large number of controls by first making B number of
permutations of the phenotype labels within the microarray experiment, and
computing the relative differences from these permutations by repeating the steps
above. The corresponding order statistics is therefore computed for each single
permutation. This means that we will permute the M and N labels between all the
patients from phenotypes I and II. (Hence during the each permutation sequence,
some of the patients from phenotype I will be labeled as from phenotype II and vice
versa. However we maintain the portion of labels for each phenotype, M labels for
phenotype I and N labels for phenotype II).
4. From each permutation b, we compute the order statistics dˆb(i) such that dˆb(1) <
dˆb(2) < ... < dˆb(p). From this set of permutations, we estimate the expected order
statistics of each single gene by calculating the expected mean of the gene rank by





5. We plot the values of dˆ(i) against dˆB(i) and a threshold ∆ which will be used to
detect genes above or below a certain threshold. An example of this plot is seen in
Figure 2.1 (image reproduced from (Tusher et al., 2001)). Specifically, we will begin
from the origin of the graph, move up to the right to find the first gene j1 where
dˆ(i)− dˆB(i) > ∆. All genes past j1 will then be considered as significantly positive.
We call this list of genes Gp (p for positively significant genes).
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Figure 2.1: Sample plot of the observed relative difference. The solid line represents the
expected mean of the gene rank while the dotted lines refer to upper and lower thresholds.
The circles refer to the corresponding genes which fall above/below the threshold. Image
reproduced from (Tusher et al., 2001).
6. To find the significantly negative genes we will start from the origin, move down to
the left and find the first gene k1 such that dˆB(i)− dˆ(i) > ∆. All genes past k1 will
then be considered as significantly negative. This list of genes will be considered
as Gn (n for negatively significant genes).
7. Therefore the combined lists, Gp and Gn from this technique gives us the list of
genes which are deemed significant as compared to the rest of the genes.
8. Finally, we can calculate the false discovery rate (FDR) by first finding the
number of average genes which are deemed significant from each of the single
B permutations using ∆. This value will be considered as the average number of
false positives.
9. The FDR will then be computed as this average number of false positives divided
by the number of genes called significant. For instance, if the average number of
false positives is calculated to be 8.4 from the B permutations, and the number of
genes deemed as significant is found to be 46, then FDR in this case will be 18%
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2.2.4 LIMMA
The LIMMA (Linear Models for Microarray Data) package (Smyth and Smyth, 2004) is
a popular tool written in R that is often used for gene expression analysis. It consists of
algorithms ranging from preprocessing to finding differentially expressed genes. One of
the useful methods in LIMMA for locating differentially expressed genes is the Empirical
Bayes analysis (Efron et al., 2001) which is described below.
We assume that there are two classes of genes — viz., differentially expressed and
non-differentially expressed genes. Suppose Z is the distribution of the (normalized)
expression level of the gene, we let:
p1 = probability that a gene is affected (2.10)
p0 = 1− p1 = probability that a gene is unaffected (2.11)
and
f1(Z) = probability density of Z for affected genes (2.12)
f0(Z) = probability density of Z for unaffected genes (2.13)
The mixture density for the two populations is then given as:
f(Z) = p0f0(Z) + p1f1(Z) (2.14)
We next estimate the value of f(Z) directly from the expression scores of the genes.
Applying Bayes rule, we obtain:
p0(Z) = Prob (gene not affected | z) (2.15)
p0(Z) = Prob (gene not affected) * Prob (z | gene not affected)/Prob (z) (2.16)
p0(Z) = p0f0(z)/f(z) (2.17)
Similarly, we obtain by Bayes rule:
p1(Z) = 1− p0f0(Z)/f(Z) (2.18)
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Given that p1 must always be positive, it must satisfy the rules that
p0 <= minf(Z)/f0(Z) (2.19)
and
p1 >= 1−minf(Z)/f0(Z) (2.20)
f0 is in fact the null density and can be obtained by carrying out a random
permutation of the phenotype labels. This allows us to estimate the value of ratio
f0(Z)/f(Z) directly from the empirical Z and null density distributions. With this ratio
we are able to calculate p1(Z), the probability that genei is differentially expressed given
the Z score.
2.2.5 Misc Techniques in Individual Gene Testing
There had also been other algorithms such as Conditional Independence (Akutsu
et al., 1999), (D’Haeseleer, 2000), (Dhaeseleer et al., 2000), (Liang et al., 1998), (Yoo
et al., 2002), Spearman Rank Correlation (D’Haeseleer, 2000), (Murphy, 2001), mutual
information (D’haeseleer et al., 1998), (Butte and Kohane, 2000), Lasso (Ghosh and
Chinnaiyan, 2004), silhouette (Rousseeuw, 1987), statistical P-values (Sohler et al.,
2000), (Rogers and Girolami, 2005) and Pearson Correlation (D’haeseleer et al., 1998).
They are basically similar in strengths and weaknesses and hence will not be elaborated
further in this section.
In addition to these miscellaneous statistical techniques, a clinical microarray project
(Wen-Son et al., 2009), which we were involved in, demonstrated that even basic
analysis (we used the basic concept of counting highly expressed genes to determine
their significance) are also capable of providing interesting results.
Because these algorithms give researchers lists of genes that are differentially
expressed, often they will have to do further processing techniques to such gene list
to obtain the biological conclusions that they seek. Thus these algorithms are very
much lacking in providing descriptive biological inferences. The next two sections deal
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with algorithms attempting to provide the researcher with biological inferences from
experimental data.
2.3 Gene Pathway Testing
This class of algorithms attempts to provide descriptive biological inferences from the
microarray experiments. These algorithms (Auliac et al., 2008; Cooper and Herskovits,
1992; Dilip and Pankaj, 2005; Djebbari and Quackenbush, 2008; Friedman et al., 2000;
Henegar et al., 2006; Ideker et al., 2002; Kauffman, 1993; Segal et al., 2003) usually
work by recreating possible pathways from the experimental data and thereby finding
out possible new associations between genes.





The most basic algorithm available is that of the K2 algorithm (Cooper and Herskovits,
1992). This algorithm is essentially an algorithm to learn a DAG from data. The K2
algorithm assumes that the variables are first ordered according to the parentage. The




old_accuracy = score(Pa(node), node, D);
findMore = true
while (findMore)
Z = node where score(Pa(node) U Z, node, D) is MAX
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new_accuracy = score(Pa(node), node, D);
if (new_accuracy > old_accuracy)
old_accuracy = new_accuracy







In this algorithm, Pa(node) denotes the parent of the node. Score(Pa(node), node,D)
denotes the score, of how well the network with node having Pa(node) as its parents
would work out as applied to dataset D. Therefore, what this algorithm does is that for
every node x, it searches through the other nodes looking for a possible candidate y as
its parent. If the addition of node y causes the score to improve, the algorithm includes
y into the parents of x. This continues until no new parents for node x can be found.
This node ordering is provided by an expert with extensive domain knowledge. Such
information can be readily obtained as a DAG from Gene Ontology and Reactome.
However as this technique builds upon knowledge that is pre-existing, the amount of
new discoveries made will be limited.
2.3.2 Sparse Candidate
An improvement to the K2 algorithm is the sparse candidate algorithm. This algorithm
omits the usage of a node ordering and caters to databases that are very sparse in nature,
making it very suitable for biological databases. This algorithm was first proposed in
(Friedman et al., 2000). Instead of carrying out exhaustive searches, heuristics are used
to determine the topology of the network. One of the crucial points of this algorithm
Chapter 2. Background Study on Microarray Analysis 23
is that edge scores are calculated via a Bayesian framework. It was used in (Friedman
et al., 2000) to analyze expression data. There are two stages in this algorithm, called the
RESTRICT stage and the MAXIMIZE stage. The pseudo-code is shown below followed
by its explanation.
function SPARSE_CANDIDATE(dataSet D, initial network B0)
while non-convergence
For each node
select parents(node) based on D and Bi
//Restrict Stage




In the restrict stage, the algorithm will assign a score to variable pairs and forming a
child-parent relationship. This score assigned can be a metric like correlation or mutual
information.
In the maximize stage, certain heuristics are used to prune the variable orderings
and pairs obtained earlier. The paper first restricted the in-degrees of each node followed
by a simple greedy hill climbing search.
There were three criterion proposed for the convergence of the algorithm. The
algorithm can converge either when the score does not increase, the candidates for the
parents do not change, or if the algorithm goes into a non-terminating cycle, when a
number of iterations with no improvement in the score is breached.
However the sparse candidate algorithm is very much limited to small datasets
because the calculation of the score in the maximize stage will be too expensive. To
simplify this calculation, the assumption of uniform data sparseness is usually made
(which might not be the case).
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2.3.3 REVEAL Algorithm
Boolean networks was first studied by (Kauffman, 1969) and (Kauffman, 1993) as a tool
for studying dynamics of complex natural systems. One of its main algorithms is that of
the REVEAL algorithm, which we will review here.
function REVEAL(networkNodes)
tempNodes = networkNodes;
for i = 1 to k
for all node in tempNodes
for all permutations of networkNodes pNodes, where
|pNodes| == i








Where networkNodes is the full set of nodes in the network, k is the maximum of input
edges in the graph for a node. The algorithm is based on concepts from information
theory (Shannon and Weaver, 1963) to calculate a metric to determine if will pNode
directly affect Node. However the algorithm becomes impractical when k becomes large
(> 4).
2.4 Gene Class Testing
The final class of algorithms (Hanisch et al., 2002; Khatri and Draghici, 2005; Liu
et al., 2009; Subramanian et al., 2005) involves analysing microarray data together with
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existing biological information to obtain biological inferences. The algorithms reviewed
in detail here are:
1. OverRepresentation Analysis (ORA)
2. Functional Class Scoring (FCS)
3. Gene Set Enrichment Analysis (GSEA)
4. Gene Network Enrichment Analysis (GNEA)
5. Signaling Pathway Impact Analysis (SPIA)
2.4.1 OverRepresentation Analysis (ORA)
ORA (Khatri and Draghici, 2005) was one of the earlier and more established algorithms
which made good usages of gene classes in finding out the decisions on genes. This
technique allows us to locate exactly specific biological mechanisms which change within
a biological pathway. There are three main steps for this method:
1. All genes are grouped according to their respective Gene Ontology (GO) classes. To
obtain a good classification, the algorithm removes classes with less than 8 genes
within the class. At the same time, it removes classes with more than 150 genes.
The reason for doing so is because too small classes would imply a class that is too
specific, and too large a class would be too general.
2. Based on the raw expression values, the ORA algorithm then segregates the genes
into two groups, "selected" and "non-selected". The selected group refers to the
genes which are seen to be overexpressed. We decide if a gene is placed in the
expressed group simply via a fold or t-test as explained in the earlier sections.
3. Hence for each group, we actually have a number of genes that are present within
the group. We need to test if the number of genes present within the group is
statistically significant. This score implies the probability of observing at least a
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particular number of genes in a class among the selected groups. This score is
much easier to explain using the following statistical example.
Suppose that we are given a set of n genes of which k belong to a category C and
a reference set of m genes of which l belong to C. Since l elements of the reference
set belong to C, by proportion, we expect to find k′ = ln/m elements in the test set.
If k is larger than k′, C is said to be enriched, if k is smaller than k′, C is said to
be depleted. To estimate the statistical significance, P-values are computed. The
P-values can be calculated in two ways: either through applying a hypergeometric
test to compute a one tailed P-value or through permutation analysis. These two
methods are described below.
a Hypergeometric test: The hypergeometric test is based on the sampling a fixed
population. Assume that 20 balls out of 100 balls in a basket are white and
we wish to calculate the probability of drawing 7 or more white balls of out 10
balls given the distribution of balls in the basket. Hence in this case, the 100
balls is the total m genes of reference set, 20 balls l genes which belong to C,
10 balls the sample set of n genes and finally the 7 balls would refer to the
k genes in the sample set which belong to C. The hypergeometric probability
can be calculated by the formula as in Equation 2.21.













b Permutation analysis: However, calculating Equation 2.21 might be in-
tractable for large values of l, m or n. Hence the other alternative would to
calculate the P-value via empirical means. For each permutation, we would
pick up n genes from the gene list m, with ri being the number of genes from
ni which is in C. This permutation procedure is repeated for I = 10, 000
iterations. The P-value can be calculated by the formula in Equation 2.22.
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p− value = Num permutations where ri > k
I
(2.22)
Thus we will be able to calculate a score for each GO set and this score implies the
probability of the class being overrepresented.
There are several limitations associated with this method. Mainly, it firstly pre-
divides the genes into two groups, selected and non selected. The method of division
is usually based on an arbitrary threshold. The choice of this threshold thus will
have an effect on the final classes of genes analyzed as "overrepresented". Another
important limitation is that after the genes are deemed as selected or unselected, they
are considered as equal regardless of their raw expression values. However, it would
make more sense to treat them differently depending on the strength of the individual
raw values.
2.4.2 Functional Class Scoring (FCS)
FCS (Pavlidis et al., 2002) was created to address some of the limitations of ORA as it
is able to obtain overrepresented groups within the GO ontology without having to pre-
divide the genes into "selected" or "unselected". Moreover, the raw microarray values
of the genes within the experiment is also taken into consideration. The details of the
algorithm are as follows:
1. The p-values of the individual genes is simply the negative log of the raw
microarray value, given by −log(Pk).
2. All genes are next grouped according to their GO classes (similarly to the FCS
algorithm).
3. The arithmetic mean – considered as a raw value for each of the individual GO
class – is calculated as
∑n
k=1−log(Pk).
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4. Permutation testing is lastly carried out to obtain a final p-value to each GO class.
We illustrate the technique for permutation testing for each GO group with this
example. For instance, the size of a particular class is k, and its raw score is r. The
algorithm will next draw out random samples of size k from the entire list of genes,
and calculate the raw score of this randomly generated group. This is repeated q
times, and the resulting distribution is next stored. The p value for the GO group
would then be the fraction of these random trials greater than the raw score r.
Hence at the end of the FCS algorithm, we get those gene classes which contain genes
are overexpressed on average. Two years later, the group at Broad Institute introduced
GSEA. Although GSEA addresses many of the limitations introduced by ORA, it is
slightly different to FCS. FCS ranks the gene groups according to the expression values
of the individual genes, while GSEA does it via the differential expression between the
gene as compared to that of a fixed phenotype. How this is done is explained in the next
portion.
2.4.3 Gene Set Enrichment Analysis (GSEA)
Of all algorithms reviewed so far, GSEA (Subramanian et al., 2005) seems to be the
most complete and rigorous in its analysis. It is one of the first algorithms that is
able to provide insights by focusing on particular gene sets, unifying genes statistically
related with an unifying theme. For GSEA, we first have to rank the genes according
to its differential correlation with a phenotype or profile. This ranking is based on the
correlation r(gj) = rj of their expression profiles with a phenotype of profile C. This list
will be known as L = g1, ..., gN . For every gene set, we will also have predefined a set of
genes, which we call S. The purpose of GSEA is to determine how this set of genes S is
distributed across the main set L. There are basically three steps to GSEA.
1. It goes through the ranked lists of genes L. With each gene it calculates an
enrichment score. We increase a running-sum statistic, Enrichment Score (ES)
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when we encounter a gene in a set S and decrease it when we encounter genes not















The enrichment score will be the maximum deviation from zero of Phit − Pmiss.
2. The p-values are next calculated using a technique known as permutation testing.
This technique estimates the significance via the set of scores of ESNULL. This
method corrects the often incorrect method of using statistical tables, which
assumes the data follows the normal distribution. The P value is estimated via
the following steps:
(a) Randomly assign the original phenotype genes to the samples in the microar-
ray experiment, thus getting a reordered gene list L. Recompute ES(S).
(b) Repeat step 1 for 1,000 permutations pi to obtain a distribution of enrichment
scores, ESNULL.
(c) Estimate the P value for S, known as ES(S, pi) from the distribution ESNULL.
3. The enrichment scores, ES(S, pi) and ES(S) are next normalised by dividing by the
mean of ES(S, pi). This yields the normalised scores NES(S, pi) and NES(S).
4. The FDR is lastly computed. This will place a cut off to the genes which reject the
null hypothesis. This cut off is determined by the estimated probability that a set
with a given NES value contains a false positive.
The FDR is defined as the probability that a given gene identified as differentially
expressed is a false positive. Here we describe the following procedure for calculating
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FDR as introduced in (Benjamini and Yekutieli, 2001) and implemented in GSEA in
(Subramanian et al., 2005). We first define a null hypothesis for each single gene gi
known as Hi. For each Hi we first obtain their t-values Ti followed by their corresponding
p values pi. Let P(1) ≤ P(2) ≤ P(3) ≤ P(m) be the ordered p-values with the hypothesis
H(i) corresponding to P(i). For FDR, let k be the largest i for which P(i) ≤ imq. We would
reject all H(i) where i = 1, 2, ..., k. For FWER, let k be the largest i for which P(i) ≤ qm . q
here refers to the threshold for the level of significance. We would reject all H(i) where
i = 1, 2, ..., k. The value of q is often given the value of 0.05.
2.4.4 Gene Network Enrichment Analysis (GNEA)
The next technique we describe (which is very similar to GSEA) is known as Gene
Network Enrichment Analysis (GNEA) (Liu et al., 2007). The GNEA consists of the
following steps:
1. Aggregate a list of gene sets associated with the biological process of interest.
These gene sets were taken from the Human Protein Reference Database, HPRD
(Prasad et al., 2009) as well as Gene Ontology (Pavlidis et al., 2004b). (HPRD is a
result of an international collaborative effort between the Institute of Bioinformat-
ics in Bangalore, India and the Pandey lab at Johns Hopkins University in Balti-
more, USA. HPRD contains manually curated scientific information pertaining to
the biology of most human proteins.)
2. Importing a global protein-protein network from biological literature, we create
a subnetwork within this global protein-protein network based on the individual
gene perturbation for each patient. This global protein-protein network is obtained
from HPRD.
3. For each gene set, we evaluate if this subnetwork is significantly expressed within
the gene set. We repeat Steps (2) and (3) for every patient.
4. Order the gene sets by the number of subnetworks where they appear enriched.
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5. Evaluate the p-value of each of these gene sets by this ranking. Gene sets with a
significant p-value are taken as transcriptionally affected across the phenotypes of
that disease.
GNEA is very similar to the GSEA (described in the preceding section). The difference
being GNEA scores only segments of pathways instead of GSEA which scores entire
pathways.
2.4.5 Network Expression Analysis (NEA)
The goal of NEA is to find a set of transcription regulators (TR) which are responsible for
driving the differential expression of other genes. Here, they define a TR as significant
if the downstream genes of its regulatory network exhibits a pattern of differential
expression significantly deviating from the distribution expected by random chance
(Sivachenko et al., 2005).
The actual distribution is measured in this manner: the absolute log-ratio value of the
gene is replicated according to the number of TRs (in-degrees) regulating this gene. This
technique allows us to observe the absolute change in log-ratio as well as its adherence
to the biological regulatory relationship. Hence if the relationship is one of activation
(suppression) and the gene is activated (suppressed), this log ratio will be given a positive
score. If conversely the relationship is one of activation (suppression) and the gene is
suppressed (activated), the log ratio is given a negative score. This creates a signed edge
distribution.
To approximate the null distribution expected from random chance, we allow the TR
to randomly pick edges bearing effect signs. A signed significant test (for example t-test)
can be applied to find the TRs that are significant.
2.4.6 Identifying regulatory modules
The method of (Segal et al., 2003) relies on inferring regulatory modules from gene
expression data. This method takes in a gene expression data set and a large
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precompiled set of candidate regulatory genes. Next, the method partitions all the genes
into modules and searches for a regulation program for each module. The regulation
program of a module specifies the set of regulatory genes that control the module and
a set of rules that determine the gene expression profile of the genes in the module in
terms of the expression of the module’s regulators.
A brief description of the method is as follows:
1. A set of candidate regulators are first compiled from the microarray experiment
and clustered into three categories—viz., downregulated, no change and upregu-
lated.
2. The aim is to assign a regulation program to as many of these candidate regulators
as possible. By a regulation program, it means a set of rules determining the
behaviour of candidate regulated genes (downregulated, no change and upregu-
lated) based on the behavior of these candidate regulators. This set of rules is
derived using a regression tree (analogous to a decision tree). Hence, the nodes of
the regression tree are thresholds on relevant candidate regulator genes and the
leaves are the behavior of the relevant candidate regulated genes. The candidate
regulated genes are next clustered into candidate modules. Then an iterative
expectation-maximization (EM) algorithm is applied to refine the modules and
find regression trees that encode the corresponding regulation programs of these
modules. Basically, in the M step, a regression tree is learned for each module. In
the E step, genes whose behaviours are best explained by the regulation program
of a module are re-assigned to the module. Care is taken such that a gene which
is part of the regulatory input to a module is not assigned to that module as a
regulated gene of the module.
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2.4.7 Signaling Pathway Impact Analysis (SPIA)
The final technique we describe is known as Signaling Pathway Impact Analysis (SPIA)
(Tarca et al., 2008). SPIA attempts to provide better biological results by calculating
significance based on the over-representation of genes within a pathway as well as the
amount of perturbation measured in each pathway. SPIA thus comprises of two separate
probabilities: PNDE and PPERT . PNDE captures probability that a given pathway is
significant based on the over-representation analysis of the number of differentially
expressed genes within the pathway. PPERT captures the probability that the pathway
will be significant based on the connections that exhibit a differential behaviour within
the pathway. PNDE can be calculated using one of the previous mentioned techniques
such as ORA and FCS.
The second probability PPERT is calculated based on the amount of perturbation
experienced within each pathway. We define the perturbation factor for each gene gi
as:






where PFgj refers to the perturbation factors of the upstream genes, and it is
normalised by Nds, the number of downstream genes. We next calculate the net
accumulated perturbation by subtracting δE(gi) from PF (gi). This subtraction is
required so that genes that are solitary will not affect the probability PPERT (since they
have already been considered in PNDE). This accumulated perturbation is hence given
by:
Acc(gi) = PF (gi)− δE(gi) (2.26)
The total net accumulated perturbation for a pathway is simply the sum of the
accumulated perturbation of the genes within a pathway A, t(A) =
∑
iAcc(gi) and the
probability PPERT is given by:
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PPERT = P (TA ≥ tA|H0) (2.27)
TA is a null distribution of tA values, obtained empirically through a bootstrapping
approach of randomising the relationship of genes within a pathway. H0 stands for
the null hypothesis, that the genes that appear as differentially expressed on a given
pathway are completely random. Finally, we calculate the probability of a pathway with
the formula:
PG(i) = ci − ci ∗ In(ci) (2.28)
where ci = PNDE(i) ∗ PPERT (i). From the list of PG(i) values calculated, the FDR
algorithm as proposed in (Benjamini and Yekutieli, 2001) was used to control the false
discovery rate at 5%.
2.5 Discussions
This literature survey of the different classes of analysis techniques suggests that
contemporary algorithms are unable to provide the researcher with sufficient biological
descriptions. For instance, techniques such as the fold change (Choe et al., 2005), t-test
(Cui et al., 2005) and SAM (Tusher et al., 2001) generate gene lists containing large
number of genes, requiring the researcher to carry out additional processing to draw
biological information from them. Furthermore since the number of samples available
for analysis is usually very small relative to the number of genes to be considered,
such techniques always suffer from the having too much false positives (due to multiple
hypothesis testing). In addition, they require specific thresholds to be set in order to
determine genes which are significantly expressed.
Techniques such as GSEA (Subramanian et al., 2005) and NEA (Sivachenko et al.,
2007) have attempted to solve these issues, for instance, incorporating prior biological in-
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formation by finding differentially expressed functional gene sets (hence providing more
biological descriptive information), introducing false discovery rate (FDR) (Benjamini
and Yekutieli, 2001) (hence alleviating the issue of multiple hypothesis testing).
However, these methods share some limitations. For instance, most of these
techniques (Subramanian et al., 2005) ignores the intricate protein connections and
protein topology within pathways. Although techniques such as (Liu et al., 2007;
Sivachenko et al., 2007) take into account protein interactions, they are considered in
a general sense, not sufficiently detailed for biological interpretation. Finally, most of
these algorithms locate entire pathways or gene sets which are differentially expressed,
ignoring the situation when only a portion of a pathway is significantly expressed (which
might be prevalent when the gene set is extremely large).
One major group of algorithms which centres on time series clustering/analysis of
microarray analysis have not been reviewed here as they are not the focus of this thesis.
However we recognise that such algorithms can be very interesting when our concept is
extended to time series data. The interested reader can refer to various key algorithms
ranging from traditional algorithms like hierarchical clustering (Eisen et al., 1998), K-
means algorithm (Tavazoie et al., 1999) to specialised clustering methods involving time
series microarray data using expression profiles, slopes (Wen et al., 1998), linear splines
(de Hoon et al., 2002) and just recently, a gene rank based approach (Yi et al., 2009).






One of the critical assumptions underlying microarray techniques which integrates
biological information (biological pathways) as a priori data into their computational
analysis is the availability of a collection of well-curated biological repositories (for
example, Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000),
Ingenuity (Ingenuity, 1998)). Specifically, we focus on three criteria: compatibility of
database (if the database is capable of merging seamlessly into the analysis technique),
comprehensivity of database (if the database contains sufficient information) and consis-
tency of database (if the database provides information consistent with other biological
databases). We review several representative biological databases and analyse their
suitability to be used as a priori biological information based on the three criteria listed
above.
Conclusions
Based on our criterion, our survey findings conclude that contemporary biological
databases are very diverse. In terms of compatibility, most repositories still relies heavily
on human intervention when manipulating biological pathways (which is impractical
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when analysing thousands of genes across hundreds of pathways for each microarray
experiment). With such little support for programming interfaces, integration of their
biological pathways into computational algorithms becomes difficult. In addition, a
popular biological pathway (the apoptosis pathway) was chosen from three representative
biological databases to investigate the level of comprehensiveness and consistency of each
database. Alarmingly, results show an extremely low level of similarity in the genes
quoted by the three databases (32% to 46%) for the apoptosis pathway. This shows that
none of the three databases are comprehensive (because other databases have information
which they do not have) and neither are they consistent (because the level of similarity
between them is consistently low). These reasons lead us to create our own unified
database cache and its API for easy integration into computational algorithms.
3.1 Introduction
As described, the current trend of microarray analysis is for prior biological information
to be integrated/used as part of the input to the analysis method. As such, it is important
that we look at the typical sources of biological information used/needed by these
modern analysis methods. In our study and search for databases (which are suitable for
integration into microarray analysis), we will be concentrating on the following criteria:
+ Are they sufficiently comprehensive individually?
Because the output analysis from algorithms depend significantly on the pre-
existing biological data, care must be taken to ensure that the data within the
biological repository is comprehensive. Otherwise the results may be highly
inconsistent as they depend largely on the biological database being used. Hence
we check if there is any single database sufficiently comprehensive to represent
most of the pathway data that is available.
+ Are the databases easily accessible to researchers who wish to use the data for
their analysis?
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In order to integrate data from these databases into algorithms, databases must
have proper software interfaces for computer scientists to connect to. Without such
an interface, integration will be highly impossible.
+ Are various biological pathway data sources consistent with each other?
In the event where we require data from different biological sources to com-
municate with one another, we require that they follow consistent molecular
representations, pathway naming conventions and exchange formats. This allows
for the inter-communication of biological databases.
3.2 Review of Contemporary Databases
In this section, we review if current biological databases are suitable for use in
computational algorithms which incorporate biological information. This review of
databases will be conducted based on the criteria listed in the previous section.
3.2.1 KEGG, Reactome
Data
KEGG (Kanehisa and Goto, 2000) and Reactome (Joshi-Tope et al., 2003) are well
established pathway databases. Their pathway data is first obtained from literature
and accurately curated and approved by experts. The focus of these two databases is to
provide pathway data as easily and seamlessly to their users as possible, they also boast
the most flexible methods of data access. For instance, both databases allow their users
to search for individual pathways and visualise them in pictorial formats. For KEGG,
they have an API (Kawashima et al., 2003) which allows computational scientists to
connect to their databases and extract pathway information from them. Hence to access
all the data from KEGG, one just executes the following API commands:
1. Execute an API call to obtain all the available pathways (for the homo sapiens
species) in KEGG.
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2. For each individual pathway, execute another API to obtain all the genes and gene
relationships for that particular pathway from KEGG.
In contrast, Reactome provides a sql data dump and also access through a SOAP api.
These data access methods allow information to be easily downloaded from their website,
allowing easier integration to computational algorithms.
Data Format
Pathways from KEGG are represented either in SOAP (returned when using API calls)
or BioPax (downloaded individually) (Kotecha et al., 2008). However we realized that
the API is not well updated and is no longer supported by the latest versions of python.
In addition the data stored in BioPax does not seem to be well maintained. Information
from KEGG remains stored in a BioPax level 1 format when the latest BioPax stands at
level 3. For Reactome, because they allow the download of the entire database in sql, it
is the most flexible and easily integrated into computational algorithms.
3.2.2 Ingenuity
Ingenuity (Ingenuity, 1998) is a commercial company which provides biological pathway
information to their subscribers. The company obtains such information using manual
curation by experts from published literature. Ingenuty provides data only in image
pictorial format. This is probably to control the rapid duplication of its proprietary
information to the different sources. Hence to obtain non-pictorial information from
Ingenuity, one must painfully determine the pathways details by extracting individual
gene and gene relationship manually.
3.2.3 NCBI
One of the main sources of biological information available online is NCBI (NCBI, 2009).
Founded more than twenty years ago, it now houses one of the largest set of free online
resources for biological information. As NCBI caters more for the users who wish to
search for online information, they focus mainly on UI design and visualisation tools
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which allow one to easily search for the genes / pathways required and to drill down
to various details of genes or relationships within pathways. Yet these databases are
inconvenient when it comes to programmatically obtaining information from them. To
illustrate this point, NCBI allows one to easily search for genes / pathways of various
species for numerous parameters within many different datasets. Executing such a
search provides one with details like which pathways the gene appears in, the list of
literature the gene is mentioned and even related pathways to the gene. However such
information is not suitable for use and integration within computational algorithms.
Indeed, NCBI has in fact even implemented steps to prevent such use of its data.
Specifically, it limits each IP address to 2,000 Internet connections on any single day,
hence preventing such scenarios from occurring.
3.2.4 Cytoscape
Cytoscape (Shannon et al., 2003) allows for the complex visualisation and editing of
biological pathways. The purpose of these tools is to help display the experimental data
on detailed diagrams of the relationships between genes/proteins in known pathways.
Thus, Cytoscape serves more as a visualisation tool and the biological information fed
into the tool depends on data generated by the user. Being an established software tool,
it has the capability of reading multiple types of input files including Graph Markup
Language, SBML and BioPAX.
3.2.5 BioCyc
BioCyc is a collection of databases where each database in BioCyc describes the genome
and metabolic pathways of a single organism. Other than the provision of data, one of
its unique propositions is the many tools within Biocyc that allow the user to navigate,
visualise and analyse the different databases. Relevant to this thesis, BioCyc allows for
the download of its data in various formats to be analysed using its tools. In addition to
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comprehensive tools and visualisers (like NCBI), BioCyc boasts its own Pathway Tools
API which allows a user to query the database in Lisp, Java and Perl.
3.2.6 SBML
We review one of the commonly used data formats in this subsection, the Systems Biol-
ogy Markup Language (SBML). This initiative was started in 2000 to work on developing
better software infrastructure for computational modelling in systems biology. It has
garnered popular usage and is supported by at least 200 biological packages. As SBML
was designed for a different use (for simulation of systems biology reactions) most of
the features within SBML might be redundant in our experiments. However, when
the current scope is expanded to include systems biology simulations, such a markup
language will prove to be very relevant.
3.2.7 Wikipathways
Data
Wikipathways (Wikipathways, 2004) is a community effort which invites professionals
to aid in providing pathway data to its repository voluntarily. In addition to curating
the data from academic professionals, Wikipathway also obtains data from the other
repositories and incorporates it into its database. This has allowed it to store a
substantial number of pathways.
Data Format
Pathway information from Wikipathways is usually in the pictorial format. However
even though Wikipathways does not provide any API or software interface, Wikipath-
ways supports a markup format known as the GPML format. This format allows a
person to plot out the exact details of the pathways because it contains the spatial
location of the genes and relationships on the pictorial format. It also allows a
direct download of all its pathways in the GPML format (Dahlquist et al., 2002).
Understanding the pathway GPML format from Wikipathways is possible, although
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non-trivial and difficult. To do so, we are required to parse through the format and




Although many commonly used pathway databases (eg NCBI (NCBI, 2009), GO (Pavlidis
et al., 2004b), Reactome (Joshi-Tope et al., 2003), HumanCyc (Romero et al., 2005), HPD
(Chowbina et al., 2009), Panther Pathways (Thomas et al., 2003), etc) were reviewed, we
have selected three representative data sources (KEGG, Ingenuity and Wikipathways)
for our analysis on data comprehensiveness among different databases. These sources
are chosen because they are representatives of three very different kinds of curation
effort. For instance, Wikipathways is maintained by a community of professional users
via the free and open wiki platform. KEGG database is curated independently by a
single lab from published literature. Ingenuity is a commercial product.
We demonstrate the lack of comprehensiveness (incomprehensiveness) of current
databases with a manual comparison on the agreement of the apoptosis pathway across
these three databases. By the term incomprehensiveness, we mean that each single
biological database is not a comprehensive representation of biological knowledge that
are acknowledged by experts to be accurate.
We define the following metrics to illustrate the diversity across databases. The first
metric, the “Gene Agreement Count” of a pathway, counts the number of genes that
are common to that pathway in all the databases. The second metric, the “Gene Pair
Agreement Count” of a pathway counts the number of “interacting gene pairs” that are
common to that pathway in all the databases. An interacting gene pair is a pair of
genes (or their products) that are directly interacting in a pathway. When calculating
the “Gene Agreement Percentage” of a pathway, we first find the total number of genes
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within that pathway for each individual database. We next select the gene count from
the database that has the least number of genes for that pathway. Finally we divide
the Gene Agreement Count by this minimum gene count to obtain the Gene Agreement
Percentage. The same technique is employed to calculate the Gene Pair Agreement
Percentage.
Results indicate an overlap range of 11%-16% for gene pairs and an overlap percent-
age of 32%-46% for genes. This is an extremely low level of agreement given a pathway
as pervasive as the apoptosis pathway. This highlights the fact that using any single
database alone is not sufficiently comprehensive. Full results are seen below in Table
3.1.
Table 3.1: Table showing data overlap for Apoptosis Pathway. This table shows the
manual calculation of the gene/gene pair differences between the different repositories for
the apoptosis pathway.
Apoptosis Pathway
KEGG x Ingenuity KEGG x Wiki Ingenuity x Wiki
Gene Pair Count: 151 vs 3374 151 vs 133 3374 vs 133
Gene Count: 89 vs 169 89 vs 82 169 vs 82
Gene Overlap: 33 38 26
Gene % Overlap: 37% 46% 32%
Gene Pair Overlap: 21 21 15
Gene Pair % Overlap: 14% 16% 11%
It should be highlighted that Ingenuity has a disproportionate high number of gene
pairs/genes. This is because in Ingenuity, entire pathways are being annotated as nodes,
which are expanded by us into its many genes/gene pairs. However, our test remains fair
as the overlap percentage count between databases is obtained by dividing the number
of genes/ gene pairs overlap by the minimum number of genes or gene pairs from either
database. Hence the large number of gene/gene pairs from Ingenuity does not affect the
fairness of the test.
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3.3.2 Incompatible Methods for Data Acquisition / Data Formats
3.3.2.1 Incompatible methods for data acquisition
All databases release their pathway information via some non-standard graphical
format. Such a graphical representation is useful for visual manual analysis. However,
it is inconvenient for large-scale computational analysis.
The primary preferred method of data analysis for pathway information for clinicians
is still the pictorial form. However, having pathway information in pictorial formats
would mean that the clinician first has to download the data in the pictorial format from
the repository. Next the clinician will have to refer to the visual representation of the
pathway individually while making his analysis manually.
While such visual representation is useful on a small scale analysis, this visual
representation is virtually useless if one is required to incorporate such information
within large scale computational analysis.
Different databases use different methods of data access. Some databases only allow
data to be downloaded via web access. Others provide flexible access to their databases
through their API.
This means that a lot of human effort and intervention is required to download
the required information for databases. For databases with no API (take for example
Ingenuity), this creates tedious challenges for software to obtain information from such
databases.
For databases whose API is public, there is no guarantee that all such API would
use the same programming languages. This causes developers to incorporate clumsy
wrappers within their applications to adhere to the API of the databases.
Fortunately most databases offer a secondary form of data acquisition which allows
one to download such pathway data in a format more friendly to algorithms than
humans.
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Yet this secondary form of data acquisition differs largely from database to database.
For instance, if one wishes to draw data from KEGG, he/she would use the KEGG API
to download the required data. On the other hand, if Wikipathways is used, a spider
must be written to scan and download data from its website. This means that if a
computational scientist wishes to incorporate pathway information within his algorithm,
he will have to customise an entirely new method for pathway extraction for each of
individual data repository!
3.3.2.2 Incompatible Data Formats
Some repositories do release their data in formats such as their proprietary markup
languages or API data structures. These are more convenient for large-scale analysis.
However such formats are always unique to their originating database.
This lack of a consistent data format means that different databases use different
formats to represent their data. Hence dedicated codes have to be written to parse,
understand and integrate data from each individual database.
For instance, KEGG allows download of the information via their proprietary SOAP
data structures while Wikipathways allow for the download of data via their format
known as the GPML format. The two formats are very different from each other and
would require the computer scientist to write dedicated parsers for each database.
We would like to point out that there have been efforts to make data exchange
formats consistent with one another. An example of such an effort is BioPax (Kotecha
et al., 2008). However, the BioPax format was first designed in 2002. A cursory
look would show that it is cumbersome for computational manipulation. An updated
API which allows fast and simple manipulation of pathways is wanting. In addition,
BioPax updates its data in a very manual fashion. For instance, the links to pathway
information in BioCyc is as old as 2005 and links to KEGG data in BioPax are dead.
Thus such an exchange format might no longer be technologically suitable.
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3.3.3 Inconsistent Data / Molecular Representations / Pathway Naming
3.3.3.1 Inconsistent Data
We define inconsistent data to mean data which differs as compared from one data
repository to another. These inconsistencies occur in gene-gene relationships where
different repositories provide different or even contradictory relationship information
between genes for the same pathway ie, Pathway I of Database 1 states that Gene
A activates Gene B but Pathway I of Database 2 states otherwise (Gene A inhibits
Gene B, Gene B activates Gene A or Gene B inhibits gene A). An example of such an
instance occurs within the KEGG’s Cell Cycle Pathway, gene RB1 activates gene TFDP1.
Ingenuity’s Cell Cycle Pathway however states that gene RB1 inhibits gene TFDP1.
Because of the inconsistency and incomprehensiveness of data (demonstrated above),
cross database queries are the intuitive solution to harness the required information
across these databases. Doing so is crucial else the microarray analysis results would be
too dependent on the databases. Meaning the researcher running his experimental data
on Database 1 will end up with a totally different set of results if he runs it on Database
2 due to the fact that the data within the pathways are already inherently different. The
latter portion of this report will demonstrate quantitatively how different the figures are
across the different databases. However incompatibilities between different databases
makes cross database accesses extremely challenging to execute. We investigate these
incompatibilities across different databases and present them here.
3.3.3.2 Inconsistent Molecular Representations
Different repositories assign different naming conventions to their pathway nodes.
These nodes can be described as proteins, genes or symbols depicting protein families.
For example, KEGG describes most of their elements as genes, Ingenuity describes them
as proteins, while Wikipathways uses a combination of both.
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We have gene names / IDs described inconsistently across different data repositories.
The problem here is heavily compounded because different databases have a different
way of referring to genes. One of such instance where this inconsistency was particularly
compounded was when the Ingenuity database used a single protein symbol "PAKC"to
represent 50 different genes on a single relationship within a pathway. This will greatly
increase the difficulty of both the computer scientist as well as the researcher in grabbing
information which will result in incomplete pathways and incomplete analysis.
Hence it is possible to miss crucial genetic relationships because of such inconsistent
representation. To obtain all relationships represented within pathways, algorithms are
required to convert all nodes to a common representation.
3.3.3.3 Inconsistent Referrals to Pathway Names
Common biological pathways in different databases are often given names with no
indication of how pathways are related to one another. For instance, KEGG may refer
to a pathway as “Wnt signaling and pluripotency” and the Wikipathways might refer to
it simply as “Wnt signaling”. Other than the fact that both pathways have the common
terms “Wnt signaling”, there is no way of knowing if the “Wnt signaling” pathway is
a subset of the “Wnt signaling and pluripotency” pathway other than through human
intervention.
This makes it difficult to determine pathways that refer to similar biological processes
(albeit sporting different pathway names). It is difficult to match and compare similar
pathways across different repositories.
3.4 Motivation for Pathway Aggregation
The prior section discussed the incomprehensiveness, incompatability and inconsistency
of current databases. This illustrates that current databases are not ready for allowing
seamless integration of their data into biological algorithms, and certainly not equipped
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to cater to the needs of newer generation of computational algorithms which relies
heavily on prior biological information.
Thus if we require that our algorithm works seamlessly with currently available
databases, we have the following options:
1. To utilize only the biological information from a single database which supports a
software interface
2. To create a separate software wrapper for each individual database that we use,
and integrate this wrapper into the algorithm
3. To create an integrated database cache and API which connects to the other
databases, allowing the researcher and algorithm to access to up-to-date from the
diverse data sources at all times.
The first option is not advisable because it only provides incorporates data from a
single data source. Hence the analysis obtained might not be totally accurate and may
well be skewed.
The second option provides us with access to multiple databases within the algorithm.
However because it depends heavily on wrapper classes within the algorithm itself, the
entire algorithm will probably go offline when one day the parent databases decide to
change part of their protocols or formats.
Hence we are left with the third and best option of providing an integrated database
with a common API. This common API will always maintain a version of the data stored
in the parent databases. At the same time it allows one to obtain the information
from the other databases from a single point of access. Because all data stored will
be stored using a standard nomenclature, accessed with a standard protocol, accessed
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in a standard format, it solves the problems of incompatabilities and inconsistencies. In
addition, several databases will be supported, to ensure that the information stored is
comprehensive.
This common API works in this manner: A local database serves as a cache, storing
data from the other repositories. Requests for information from the different repositories
are directed to this cache to obtain the required information. This is achieved also
via software wrapper classes. To ensure that our interface is always kept up to date,
automatic incremental updates are run periodically to extract the latest information
from the different repositories. This process creates a unified interface for the different
databases, as well as a unified database where graphs of the same pathway are merged.
3.5 Discussions
In spite of the advancements in microarray analysis explained in the previous chapter, it
is still challenging to draw biological conclusions from today’s microarray experiments.
The main source of the difficulty is that the number of samples available for analysis
is usually very small relative to the number of genes to be considered. It is often
the case that many genes are statistically significant according to the wide variety
of computational and statistical analysis algorithms. Yet there is little concurrence
between the genes selected by different algorithms. Furthermore, the genes selected
by these algorithms do not always provide an insight that is biologically consistent or
biologically interpretable.
In order to obtain results that are more biologically meaningful, it is important to
incorporate information from biological repositories into the analysis of microarray data
(Soh et al., 2007). Indeed, most of the new generation of algorithms (under the category
of “Gene Class Testing” in the previous chapter) incorporate information from biological
pathways into microarray data analysis (Goeman et al., 2004; Khatri and Draghici, 2005;
Subramanian et al., 2005).
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Examples of the new generation of microarray data analysis algorithms that in-
corporate biological pathway information into the analysis process include ORA (Over
Representation Analysis) (Goeman et al., 2004; Pavlidis et al., 2004a), FCS (Functional
Class Scoring) (Goeman et al., 2004; Pavlidis et al., 2004a), GSEA (Gene Set Enrichment
Analysis) (Subramanian et al., 2005), ErmineJ (Lee et al., 2005) and Pathway Express
(PathwayExpress, 2009).
Examples of databases which these algorithms reference are: NCBI (NCBI, 2009),
KEGG (Kanehisa and Goto, 2000; Kanehisa et al., 2006; Ogata et al., 1999), Ingenuity
(Ingenuity, 1998), GO (Gene Ontology) (Pavlidis et al., 2004b) and Wikipathway
(Wikipathways, 2004). In terms of source authority, both KEGG and Ingenuity derive
their data from published work while Wikipathways first derive their’s from several
established databases (eg KEGG, Netpath) and are subsequently curated by the research
community.
However these biological databases are very diverse, making it extremely laborious to
carry out even simple queries across databases. To make matters worse, inconsistencies
and incompatibilities between different repositories render the individual databases less
effective for collaborative purposes.
This inconsistency is worsened because the boundaries of signaling pathways are not
that clearly defined scientifically. For example, the pathway "MAPK Cascade" probably
has no clear consistent definitions in the literature hence making the question of exactly
which genes to include quite subjective (Green ML, 2006).
ORA (Khatri and Draghici, 2005), FCS (Pavlidis et al., 2002) and GSEA (Subramanian
et al., 2005) are all examples of algorithms that incorporate information from biological
databases. Both ORA and FCS use the GO database to select relevant genes according to
their GO classes. GSEA uses their proprietary database (curated from various sources)
for gene selection.
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The importance of the accuracy and comprehensiveness of the biological pathway
information used should be clear from the review above of modern microarray data
analysis algorithms. For instance, clinicians may potentially end up with different
results and conclusions depending on the database they group their genes by! Hence it
is crucial that we did a review of some of the popular biological databases to determine
their suitability to algorithms.
This shows that current databases are not suitable for seamless integration into
microarray analysis because of incompatible, inconsistency and incomprehensive issues.
Hence it was determined that the best option was to create an aggregated database
cache with its own API, henceforth allowing different algorithms to utilize biological
information from different databases from a location. Doing so solves both the problems
of incompatabilities and inconsistencies. Because a few databases will be supported, we
will ensure that the information stored within the databases be as comprehensive as
possible. The implementation details of this database cache will be outlined in the next
chapter.
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CHAPTER 4
Pathway API — Methods
Chapter Synopsis
Summary
The previous chapter (Chapter 3) argued for the need to create our own biological repos-
itory (for integration within computational analysis) because of the lack of consistency
and comprehensivity and compatibility of current databases. This chapter explains
the technical challenges and techniques we employed in designing and creating our
own biological repository. We focus on three main aspects of the design: (1) How we
formalise key biological features within pathways to computational database entities. (2)
How we extract, store and update these key features from publicly available pathway
databases (in particular, we focus on three representative databases, KEGG, Ingenuity
and Wikipathways) (Soh et al., 2009). (3) Finally we describe and provide a short
specification of the application programmable interface (API) to the database such that
others will be granted easy access protocols for integration into their computational
algorithms.
Conclusions
The techniques presented in this chapter aim to create our unified database which
is comprehensive, consistent with other databases and compatible for integration into
computational microarray algorithms. We attempt to achieve data comprehensiveness
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by integrating biological data from three representative biological repositories. Data
consistency is achieved through the standardisation of nomenclature and data formats.
We ensure that data from this unified biological resource is both compatible and easily
accessible through simple web based http API calls.
4.1 Introduction
The previous chapter showed how current databases are ineptly equipped to be easily
integrated into computational algorithms which require biological information. Faced
with this situation, the solution proposed was to create our own database. This chapter
shows the methods adopted in creating such a database cache supported with an API.
To create such an API, we first have to define the type of information which is crucial
for use for the database, followed by obtaining such biological data from respective data
sources. The key components behind such an API are:
+ Pathway Formalisation: Key features within pathways
+ Database Cache: How we store, extract and update the data
+ API Implementation: Short specification of the API
4.2 Pathway Formalisation
Pathway databases supply many informative features that are useful for the purposes
that these databases were originally intended for. However, for use in gene expression
analysis algorithms such as ORA, FCS and GSEA it is sufficient to capture only two key
features in these pathway databases.
One feature defines all the genes within the pathway while the other defines gene-
gene relationship within the pathway. Here we only consider two relationships between
genes: activation and inhibition. (Gene relationships in metabolic pathways are
formalised in the same manner based on how they catalyse adjacent steps within the
pathway. For metabolic pathways, relationships between adjacent proteins are indicated
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as neutral, meaning neither activating or inhibiting. This approach for metabolic
pathways is similar to the approach adopted by KEGG.) This formalisation helps to
organise and streamline information within pathways.
For illustration, we redraw a KEGG pathway in Figure 4.1. The original pathway is
in Figure 4.2. The component depicting genes within a pathway refers to the individual
genes MDM2, TP53, etc. The other component depicting gene-gene relationships refer
to relationships (eg MDM2 inhibits P53, ATM activates CHK1) in the pathway diagram.
Figure 4.1: A selected portion extracted from the Cell Cycle KEGG Pathway (from Figure
4.2) and redrawn here.
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Figure 4.2: The original Cell Cycle KEGG Pathway (Kanehisa and Goto, 2000), extracted
from the KEGG database and reproduced here.
4.2.1 Representation of Genes
As mentioned earlier, one of the inconsistencies across different databases is the
inconsistent usage of proteins, genes or protein lists within pathway data. To address
this issue, all gene or protein representations are converted to their corresponding NCBI
Gene ID. The NCBI Gene ID is obtained by issuing and parsing the results of the query:
http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=gene&cmd=search&term=Y+homo+sapiens
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Where the symbol Y refers to the gene name. Executing this query iteratively across
all the genes/proteins within the pathway provides us with the Gene IDs within the
pathway. This common terminology reconciles gene naming inconsistencies across the
different repositories.
4.2.2 Representation of Genes-Gene Relationships
There are only two types of relationships present between genes: inhibition and
activation. These two relationships are illustrated in Figure 4.3 where we see ATM
activating CHK1, CHK2 and MDM2 inhibiting p53. Figure 4.4 shows the explicit
relationship between MDM2 (as the inhibitor) and p53 (as the inhibitee).
By constructing such inhibitor-inhibitee/activator-activatee relationships, investiga-
tors explicitly know the exact relationship of genes within pathways. This allows them
to analyse the adherence of these relationships in their experimental data.
Figure 4.3: Images depicting the two types of gene relationships considered. Left: Type
1 relationship where gene ATM activates both genes Chk 1 and Chk2. Right: Type 2
relationship where gene MDM2 inhibits gene p53. (Image reproduced from (Soh et al., 2007))
Inhibitor Inhibitee
MDM2 p53
Figure 4.4: Figure showing distinctly the relationship between genes p53 and MDM2.
MDM2 is explicitly referred to as the inhibitor and p53 referred to as the inhibitee.
4.3 Database Cache
In the following sections, we will be discussing on the storage, extraction and updating
the data for our unified database.
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4.3.1 Data Storage
We maintain a database cache to store information from the other pathway repositories.
To ensure fast response to users, all queries submitted are directed to this database
cache. Our database cache is kept up to date with a set of automated scripts written to
do periodic incremental updates from the other databases.
The 3NF database schema used to store the captured data is shown in the Figure 4.5.
Note that the fields in bold are the names of the table. The underlined fields are the
primary keys of the table.
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4.3.2 Data Extraction
4.3.2.1 Wikipathways
Data from Wikipathways are publicly available via their proprietary file format known
as the GPML format (Dahlquist et al., 2002). Hence we first obtain the pathway IDs
of all the pathways present within the Wikipathways database. The next step involves
iterating through these ids to obtain the GPML file associated to each pathway ID. The
final step parses the GPML format to obtain the pathway genes and associations.
All pathways within Wikipathways are obtained by issuing and parsing the query:
http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage
A simple parsing of this page gives one the list of all the pathway names present
within the Wikipathway database. The following webquery is issued to obtain the
pathway information in a text format. Here, Wikipathways term it as a GPML file.
The corresponding GPML file for each pathway is obtained with this query:
http://www.wikipathways.org//wpi/wpi.php?action=downloadFile
&type=gpml&pwTitle=Pathway:Homo%20sapiens:X
Where X refers to the name of the pathway.
The GPML format is designed towards the visual display of pathway information.
Hence it contains detailed coordinate information about the spatial location of genes and
arrows/t-bars (which depict activating/inhibiting relationships). Yet how these genes are
related is not described in the GPML specifications. A parser is therefore needed to
understand these spatial descriptions and extract the relevant genes and associations.
The different components of the parser are:
+ Gene Extraction: Extraction of genes from the GPML file requires the identifica-
tion all occurrences of the GPML DOM attribute name: “DataNode”. This enables
the parser to obtain the Gene Name, Gene NCBI ID and the spatial coordinate
locations associated to this datanode.
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+ Spatial Clustering: Activating/inhibiting relationships are described across gene
clusters spatially. Therefore the genes have to be spatially clustered to determine
spatially the activator/activatee or inhibitor/inhibitee relationships.
An example is reproduced in Figure 4.6. Here the genes CDK2, CYCE inhibits the
entire cluster of ORC genes. Hence we group the genes CDK2, CYCE together as
one cluster, and the ORC genes as another.
Using the coordinates from the genes obtained above, a nearest neighbour tech-
nique is employed to organise the genes into their respective clusters. Basically
this nearest neighbour algorithm groups genes together if their distance apart is
below a threshold (empirically determined as 100 pixels). A short pseudo-code of
this algorithm is as follows:
Chapter 4. Pathway API — Methods 60
function nearest_neightbour(nodelist n)
set nodecluster = n
while (change)
change = false
For each cluster1 in nodecluster
For each cluster2 in nodecluster
if dist(cluster1, cluster2) < threshold








We basically treat each individual gene node as a node cluster. All the node clusters
are cycled with two nested for loops. If we find within the nested loop that there are
two gene clusters whose distance are below a certain threshold (100 pixels here),
we combine these two clusters. The algorithm continues to run until the clustering
of the genes remains constant.
The potential running time for this algorithm is O(n4) but the average running
time is O(mn2) where m refers to the number of clusters present.
This gives us the exact spatial coordinate information of each gene cluster. This
allows us to form relationships between gene clusters (explained in the next
section).
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+ Relationship Extraction: Relationships within the GPML files are represented
by the attribute keywords: “Arrow” for activating and “T-Bar” for inhibiting. These
attributes provide their spatial coordinate information of activating and inhibiting
relationships. The challenge here is associating the correct gene clusters to each
relationship.
We can thus easily locate all activating and inhibiting relationships within a
pathway. The challenge then becomes associating the correct inhibitee / inhibitor
or activatee / activator gene clusters to each relationship. This we carry out via
image processing means.
By representing relationships as a straight line, this relationship line in the spatial
space is extended until it intersects with the nearest gene clusters on both sides of
it. This technique assigns the activator/activatee or the inhibitor/inhibitee gene
clusters to both sides of the relationship.
We refer to an earlier diagram in Figure 4.6. Extending the relationship line, the
relationship spatially intersects gene clusters CDK2 and CYCE and the ORC gene
clusters. This assigns gene cluster CDK2 and CYCE as inhibitors and the ORC
gene cluster as the inhibitee.
The equation of the relationship line, can be calculated using the geometry
equation
y = mx+ c (4.1)
We next test each gene cluster (found in the previous section) to assign it to its
proper relationship. The pseudocode is as follows:
Chapter 4. Pathway API — Methods 62
function finding_relationships(relationships rs, nodecluster n)
For each relation in rs
For each cluster1 in nodecluster
if intersection(cluster1, relation)







The innermost loop takes note that we assign the most suitable gene cluster to the
relationship (By most suitable, here we refer to the cluster spatially nearest to the
relationship).
For metabolic pathways (because the gene relationship is neither activating or
inhibiting), the GPML attribute keyword is simply a “Solid” line attribute. In such
instances, the relationship type attribute to the gene pair would be “neutral”.
4.3.2.2 KEGG
Data is obtained from KEGG via a series of API calls and processing the data (SOAP
format) returned. An API call is issued to obtain all the pathways first. This returns
all the relevant pathway IDs stored within KEGG. Separate API calls are made for each
pathway IDs to obtain the genes and gene pairs present for each specific pathway.
The API call to obtain all the pathways for homo sapiens is: serv.list_pathways(“hsa”)
where “serv” refers to the created wdsl object to communicate with KEGG and hsa refers
to the “homo sapiens species”.
The API call for gene and gene pair extraction from a KEGG pathway are:
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+ Gene Extraction: serv.get_genes_by_pathway(X)
+ Gene Pair Extraction: serv.get_element_relations_by_pathway(X)
where X refers to the pathway ID within KEGG.
The data returned from the API calls is parsed, extracting the critical components
and populating them into the database.
4.3.2.3 Ingenuity
All pathway repositories allows users to download pathway data in pictorial formats.
However, such pictorial formats are usually useless to automated computational analy-
sis. Hence most repositories would support downloading of their data in a text format
too. Ingenuity though supports downloading of pathway data in a pictorial format. This
forces our pathway data extraction from Ingenuity to be done manually, an extremely
painful and time consuming process.
In fact, as Ingenuity is a commercial company and earns its revenue stream from
charging the download of data, it is not surprising that Ingenuity legally prevents batch
download of data from Ingenuity (hence only releasing information in the pictorial
format). We have taken this legal issue into consideration and have disallowed the
download of Ingenuity’s information from our servers.
4.3.3 Data Updates
An expiry date is assigned to all information stored within our database cache.
Upon reaching the expiry date, scripts are triggered to run, automatically extracting
information from the reference databases (KEGG and Wikipathways) and populating it
into our database cache.
4.4 API Implementation: Short specification of the API
We provide a single common API to access the different databases. This common API
works in this manner: A local database serves as a cache, storing data from the other
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repositories. Requests for information from the different repositories are directed to
this cache to obtain the required information. To ensure that our interface is always
kept up to date, automatic incremental updates are run periodically to extract the latest
information from the different repositories. This process creates a unified interface for
the different databases, as well as a unified database where graphs of the same pathway
are merged.
The database is available at www.pathwayapi.com. The recommended requirements
are: 1 Mbps internet connection, 1GHz Processor, 512MB Memory. The database cache
currently stores a total of 397 gene pathways, 21,314 genes and 60,900 gene pairs. From
this API, access to pathways from both the integrated and the individual sources are
provided. Further details of this interface can be found at (PathwayAPI, 2009).
The API was written in PHP, and data transfer in JSON format. We have chosen
JSON over SOAP or XML because:
+ JSON is lighter in weight, transmitting less information over the internet. Client
applications therefore executes faster.
+ JSON has the ability to easily represent most general data structures such as
records, lists and trees.
+ With SOAP or XML, dedicated parsers are always required on the client. JSON
is innately supported by most programming languages, eliminating the need for
client parsers.
Some implemented functions of the API include:
+ GetDatabase: Returns all repositories supported by our API. No parameters
are required for this function. The usage example is: www.pathwayapi.com/
api/API_GetDatabase.php and the sample results returned is:
[“KEGG”,“Ingenuity”,“Wiki”].
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+ GetGene: Returns the NCBI GeneID of the gene. This function takes the name
of the gene as the parameter. An usage example is: www.pathwayapi.com/
api/API_GetGeneID.php?SearchGene=MDM1. The format returned is:
[[“MDM1”,“252867”],[“MDM1”,“56890”]]. In this case, there are two separate gene
ids that are returned.
+ GetDBPathways: Returns the all pathway names and IDs of a specific repository.
Only the database name needs to be submitted to the function. For instance,
www.pathwayapi.com/api/API_GetDBPathways.php?DatabaseName=KEGG. Here,
the following will be returned: [kegg{“1”: {“DatabaseName”: “KEGG”, “Pathway-
Name”: “Glycolysis Gluconeogenesis - Homo sapiens (human)”}, “2”:{“Database-
Name”: “KEGG”, “PathwayName”: “Citrate cycle (TCA cycle) - Homo sapiens
(human)”}, etc...] where “1” refers to the Pathway ID, “KEGG” refers to the name
of the database and “Glycolysis Gluconeogenesis...” refers to the name of the
pathway.
+ GetPathway: Returns the pathway ID of a specific pathway of a repository. Posting
the name of the pathway in this manner:
www.pathwayapi.com/ api/API_GetPathway.php?Pathway=Apoptosis will return
the jason format like: [[“Apoptosis - Homo sapiens (human)”,“KEGG”,"140”],
[“Apoptosis Signaling”,“Ingenuity”,“210”]].
In this instance, this implies that there are at least two pathways with the
“Apoptosis” keyword witin their pathway names. The two pathways occurs in the
KEGG databases and in the Ingenuity databases. The pathway id associated to
each is 140 and 210 respectively.
+ GetPathwayGenes: Returns all the GeneID of a specific pathway of a repository.
Providing the pathway ID to this function returns the user all the genes within
this pathway in this manner:
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www.pathwayapi.com api/API_GetPathwayGenes.php?Pathway=7 Resulting in:
[“231”:“AKR1B1”,“2538” :“G6PC”,“2548”:“GAA”,“2582”:“GALE”] where “231” refers
to the gene ID and “AKR1B1” refers to the name of the gene.
+ GetGenePathways: Returns all the pathways which a gene occurs. In the opposite
note, this function returns all the pathways which a supplied gene occurs in.
http://www.pathwayapi.com/ api/API_GetGenePathways.php?SearchGene=7157 We
obtain the following database pathway pairs: [“128”:“MAPK signaling pathway
- Homo sapiens (human)”,“134”:“Cell cycle - Homo sapiens (human)”,“135”:“p53
signaling pathway - Homo sapiens (human)”] In this example, “128” refers to the
Pathway ID and "MAPK signaling pathway - Homo sapiens (human)" refers to the
name of the pathway.
+ GetPathwayInteractions: Returns all interactions within a pathway of a database.
Passing in the ID of the pathway, the API returns all the interactions within the
pathway. www.pathwayapi.com/ api/API_GetPathwayInteractions.php?Pathway=7
will result in [[“231”,“AKR1B1”,“2584”,“GALK1”,“Activate”]
,[“231”,“AKR1B1”,“2585”,“GALK2”,“Activate”]] In the example above: “231” and
“2584” refers to the IDs of the gene pair “AKR1B1” and “GALK1” refers to the
corresponding genes of the ID.
+ GetPathwayDiff: Get the differences in genes and gene interactions across path-
ways. This function requires the user to supply the IDs of the two pathways he/she
wish to check on the difference in. The call below shows the difference in genes
and gene interactions between pathway 7 and pathway 8. www.pathwayapi.com/
api/API_GetPathwayDiff.php?Pathway1=7&Pathway2=8
This gives the following results where: [[“AKR1B1”,“G6PC”,“GAA”,“GALE”,“GALK1”],
[“ALDH2”,“ALDH3A1”], [“AKR1B1_GALK1”,“AKR1B1_GALK2”,“AKR1B1_GLA”],[]]
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Where [“AKR1B1”,“G6PC”,“GAA”,“GALE”,“GALK1”] refers to the genes within
pathway 7 not in pathway 8.
[“ALDH2”,“ALDH3A1”] refers to the genes within pathway 8 not in pathway 7.
[“AKR1B1_GALK1”,“AKR1B1_GALK2”,“AKR1B1_GLA”] refers to the gene inter-
actions within pathway 7 not in pathway 8.
[] refers to the gene interactions within pathway 8 not in pathway 7. This set is
empty because all interections in pathway 8 are in pathway 7.
4.5 Example Usage of API
Here we show an example on how we use this API to find out the pathways with the
most number of differentially expressed genes within a microarray experiment.
1 Find out the genes within the microarray experiment which are differentially
expressed. This step can be easily achieved by using the t-test or any other
statistical test mentioned in the earlier chapters.
2 Find out which pathways these genes belong to. For each gene found differentially
expressed in the previous step, we carry out iteratively the following API call:
http://www.pathwayapi.com/api/API_GetGenePathways.php?SearchGene=
individual_gene_id where individual_gene_id refers to the gene ID for each indi-
vidual gene within the microarray experiment
This gives us a whole list of pathways where the gene is found to be differentially
expressed.
3 Depending on the number of occurrences each pathway appears, as well as the
number of genes present within the pathway, we can assign a score to each
individual pathway. The pathway with such highest score can be deemed as
the pathway that is most significant (due to the large number of differentially
expressed genes within that pathway) for the microarray experiment.
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4.6 Discussions
The advantages of having such an aggregated database with common API are:
+ Consistent data Where possible, we have combined information of similar path-
ways from different repositories. Thus if Gene A is quoted in Pathway P of
Repository X, and Gene B is quoted in Pathway P of Repository Y, both Genes
A and B are quoted in Pathway P of our new repository. This goes the same as well
for the pathway relationships.
+ Consistent referrals to gene names We refer to all proteins and genes via consistent
NCBI gene id-s. If a protein is being referenced, we represent that protein as the
genes it translates to.
+ Consistent methods for data acquisition Computer scientists can use our single
API to obtain pathway information from supported repositories. This reduces the
need for the computer scientist to customise a new acquisition method based on
the repository. In addition, data returned is in a single consistent format.
A single microarray experiment contains at least 10,000 genes. If we were to just
require to find out the pathways each gene appears in, it would already take 10,000 API
calls and this might take some time. To expedite processing, we have allowed users to
download the entire database in a SQL dump. This allows the user to host his/her own
data. Information that the user requires can be obtained directly through SQL queries,
thereby reducing processing time.
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Figure 4.5: The database schema used for our pathway api database (PathwayAPI, 2009).
Each column represents a separate table. The name of the table is represented as the first
row in each column. The rest of the rows within each column refers to the table entities. The
underlined rows refer to their primary keys.
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Figure 4.6: A diagram depicting how relationships would look like in Wikipathways
(Wikipathways, 2004). Here, the genes CycE and CDK2 are depicted as inhibiting the ORC
class of proteins, which contains genes ORC1L, ORC2L, ORC3L, ORC4L and ORC6L
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CHAPTER 5
Pathway API — Evaluation
Chapter Synopsis
Summary
Chapter 4 outlined our techniques and methodology for the creation of our unified
database. This chapter evaluates our database to ensure that it is consistent, comprehen-
sive and compatible for integration into computational microarray algorithms. We make
quantitative evaluations by comparisons between three databases (KEGG (Kanehisa and
Goto, 2000), Ingenuity (Ingenuity, 1998) and Wikipathways (Wikipathways, 2004)). This
comparison is made by calculating the percentage overlap in genes, gene pairs and
pathways across these three datasets. Finally a qualitative examination is being done
to arguing that our standardised nomenclature (such as gene references and key pathway
features), makes our database compatible for integration into computational techniques.
Conclusions
After unifying information from three different biological databases (KEGG, Ingenuity,
Wikipatways), we show that indeed there is a low level of consistency among them (specific
figures provided below). Generally, the level of consistency for genes in similar pathways
across databases ranges from 0% to 88% while the level of consistency for interacting
genes pairs ranges from 0%-61%. Hence biological information stored within our unified
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database is more comprehensive information as compared to the individual databases
KEGG, Ingenuity or Wikipatways.
Qualitatively, because we (1) unified pathway data from three independent biological
sources, (2) created consistent data access methods and formats, (3) standardised
nomenclature such as gene references and pathway key features, researchers will be able
to access complete information (from different databases) easier by using a single access
method (PathwayAPI) and using standardised nomenclature.
5.1 Introduction
Pathway API was implemented over a period of one to two years. A version of the
system has been made public online at www.pathwayapi.com. Access to data within
the database can be achieved by invoking the database API. The entire database has




Pathway databases (eg KEGG, Ingenuity, Wikipathways) have always been assumed
to be consistent because they share a common data source: published literature
(Wikipathways is based on established databases like KEGG or Netpath, hence sharing
the same roots of published literature). We show here that this assumption is not true.
We reuse the definition that was done for the gene pair count and the gene agreement
count in the earlier chapter. In the case of metabolic pathways, we define an interacting
gene pair as proteins that catalyse adjacent steps in the pathway.
The three databases represent some of their pathway entries not as genes but as
proteins or symbols depicting protein families or classes. In such instances we replace
all such proteins and symbols with the genes they represent. For example, suppose that
A activates B within a pathway, where A and B are symbols representing protein classes
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that are products of 3 genes and 2 genes respectively. We replace A activates B by 6 new
activating relationships. We claim the validity of this replacement method because it
exactly captures all the genes and relationships the original curator had intended. All
statistics calculated here are based on the expanded relationships.
As listed in the earlier chapters, our investigation into database consistency began
with a manual comparison on the agreement of the apoptosis pathway across databases.
This achieved an extremely low level of agreement within a range of 11%-16% (Gene
Pair Agreement Percentage) and 32%-46% (Gene Agreement Percentage). For clarity,
we reproduce the results once again in Table 5.1.
The next step involves an automated extraction for the apoptosis pathway between
the databases. The results are shown in Table 5.2. The results indicate a range of 12%-
14% (Gene Pair Agreement Percentage) and 30%-46% (Gene Agreement Percentage).
This is indicative that the above mentioned gene matching procedure is reliable and not
missing significant numbers of equivalent genes.
Table 5.1: Table showing data overlap for apoptosis Pathway. This table shows the
manual calculation of the gene/gene pair differences between the different repositories for
the apoptosis pathway.
Apoptosis Pathway
KEGG x Ingenuity KEGG x Wiki Ingenuity x Wiki
Gene Pair Count: 151 vs 3374 151 vs 133 3374 vs 133
Gene Count: 89 vs 169 89 vs 82 169 vs 82
Gene Overlap: 33 38 26
Gene % Overlap: 37% 46% 32%
Gene Pair Overlap: 21 21 15
Gene Pair % Overlap: 14% 16% 11%
Table 5.2: This table shows the calculation of the gene/gene pair differences between the
different repositories for the apoptosis pathway based on the automated processing described
in this paper.
Apoptosis Pathway
KEGG x Ingenuity KEGG x Wiki Ingenuity x Wiki
Gene Pair Count: 182 vs 3486 182 vs 155 3486 vs 155
Gene Count: 84 vs 185 84 vs 79 185 vs 79
Gene Overlap: 28 36 24
Gene % Overlap: 33% 46% 30%
Gene Pair Overlap: 22 22 18
Gene Pair % Overlap: 12% 14% 12%
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We subsequently followed up with an automated extraction and comparison between
the databases. The ranges are 0%-88% (Gene Agreement Percentage) and 0%-61% (Gene
Pair Agreement Percentage). These numbers confirm our earlier suspicion that there is
an extremely low level of consistency between the databases. For results depicting the
level of overlap for the other pathways refer to Table 5.3, Table 5.4 and Table 5.5.
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5.2.2 Database Comprehensiveness
This section conducts an independent audit on the comprehensiveness of individual
pathway databases.
The pie charts in Figure 5.1 and Figure 5.2 shows the comprehensiveness of databases
(with respect to its gene and gene pairs). One can tell from the pie charts that the
amount of overlap is very low, depicting a low level of comprehensiveness for all three
biological databases analysed.
Figure 5.1: Pie charts depicting gene overlap proportions. The lighter shade refers to the
proportions of unique genes while the darker shade refers to proportions where there was an
overlap of genes. (Graphs generated with Google charts (Google, 2009))
Figure 5.2: Pie charts depicting gene pair overlap proportions. Similarly, the lighter shade
refers to the proportions of unique gene pairs while the darker shade refers to proportions
where there was an overlap of gene pairs. (Graphs generated with Google charts (Google,
2009))
We use a metric called “Pathway Comprehensive Score” to study database comprehen-
siveness. This metric first counts the total number of unique pathways present within
the three databases (Ingenuity, KEGG and Wikipathways). A score for each database
is next calculated by dividing the number of pathways a database hosts by the total
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number of unique pathways. A score of 0 indicates that the database hosts nil pathways
while a score of 1 indicates it hosts all the pathways.
KEGG achieved the highest score of 0.59. This was followed by Wikipathways (0.42)
and Ingenuity (0.13). This short study indicates that KEGG Pathways remains the most
comprehensive of all databases. This is illustrated by a Venn diagram in Figure 5.3.
Figure 5.3: Venn diagram depicting overlapping pathways across the three databases,
KEGG, Ingenuity and Wikipathways.
We match pathways across separate databases via the following technique: Given a
pathway X in database 1, we generate a list of pathways Y in database 2. This list Y is
ranked according to the length of the longest common substrings with pathway X. This
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list is next manually scanned to obtain the pathway which has the closest nomenclature
match to pathway X.
To validate this technique of matching pathways, we did the following: Given a
pathway X in source 1, we match it against the top three pathways in source 2 that
has largest gene overlap with pathway X. 94% of the time we obtained a pathway match
identical to the pathway we would have achieved if we had done by our technique.
In addition, for the remaining 6% of these pathways, we carry out the following
comparison: Suppose that P-Q are the pathway pairs found by our algorithm and P-
R are the pathways found by matching the genes. We found out that the number of
gene pair intersections is higher in the P-Q pathway pair compared to P-R pathway pair.




Microarray algorithms produce different (subjective) results depending on the database
being used. This may cause further inconsistencies and confusions in analysis. This
is especially accentuated because the boundaries of signalling pathways are not that
clearly defined. Therefore scientifically, making the question of exactly which genes to
include in pathways is quite subjective.
To make databases consistent, our strategy is to first aggregate all similar pathways
from the different databases. This is followed by combining the gene and gene pair
information for each pathway.
This solves the problem where we have genes or gene relationships lacking from
certain pathways. Hence we can use pathway which is present across the different
repositories.
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5.3.1.1 Consistent data access and formats
Having obtained the data and having control over its data access and formats, we
can accommodate several standard methods of accessing the data. As mentioned, we
have written an API to provide quick access to the data online. However for serious
practitioners who would require huge amounts (> 10,000) of API data connections daily,
using the API for such purposes would be impractical. For such users, we would
recommend downloading our sql dump which contains the entire collection of data
available on our database. Doing so would allow the user to setup a database on his
own localhost and access the data using very fast sql queries instead.
5.3.1.2 Consistent Molecular Representation
Our representation of proteins, genes etc are a lot more consistent because we convert
all such molecular representations (eg genes, proteins, pathways) into individual genes,
and represent them by their respective gene IDs (obtained from NCBI).
5.4 Discussions
It is widely accepted that analysing microarray experiments with biological information
provides biological inferences of a greater detail. Examples of such analysis are
(Draghici et al., 2007; Efroni et al., 2007; Tian et al., 2005).
However, such techniques run into issues if the data source used is not consistent or
comprehensive. For example, using the same technique on a different database yields a
differing analysis result.
Faced with such an issue, the solution is to integrate biological information across
different data sources to obtain a more wholesome analysis. Yet the incompatibility of
the different data sources renders this option extremely challenging.
Furthermore, our investigations reveal low levels of consistency, comprehensiveness
and compatibility among three popular pathway databases (KEGG, Ingenuity and
Wikipathways).
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Our strategy of addressing this issue is to create an API (described in the previous
chapter) which gives researchers access to various pathway databases of their choice as
well as to an integrated database. This integrated database resolves all incompatibilities
because now we have one API and one data format. The integrated database is also
more comprehensive because it is the union of the data sources. Every gene/edge in
any of the three data sources is also in the integrated database. Furthermore, the
integrated database is equipped with a API to allow the user to conveniently identify
inconsistencies and to resolve them in accordance to his specific application needs.
To ensure fast responsiveness, API connections are made towards a central unified
database which keeps a cached copy of the records of the other databases. To ascertain
that the cached entries are always kept up to date, entries from the cache are flushed
periodically and automatically updated again from the reference databases.
There are many efforts on the aggregation of pathways data (like Reactome (Joshi-
Tope et al., 2005), PathCase (Elliott et al., 2008; Krishnamurthy et al., 2003) and
MappFinder (Doniger et al., 2003)). There are also many tools to explore, edit and
export biological pathways (such as GenMapp (Salomonis et al., 2007), BioCyc (Karp
et al., 2005), PathVisio (van Iersel et al., 2008), Cytoscape (Shannon et al., 2003)).
However manipulation of pathways in these earlier works still relies heavily on
human intervention with little provision for programming interfaces. Indeed projects
like Cytoscape and Pathcase have very sophisticated GUI visualisation tools to help
researchers manipulate pathways. Yet such visualisation tools are impractical when
one is required to analyse of thousands of genes across hundreds of pathways for each
microarray experiment. The nearest to a programming interface was the provision of a
AQI (Application Query Interface) (Elliott et al., 2008) where users can recall predefined
queries using a web interface. Yet the scope of such queries remains limited and
insufficient.
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One issue we have with most data aggregators is their lack of explanation on how
their data is kept updated. For instance, little mention is made on how the aggregated
data is updated from the various repositories. In fact this issue is acknowledged in
(Elliott et al., 2008). Here we set an expiry date for every data entry and once it expires,
automated scripts are fired off to extract data from the data sources and populate them
within our database cache.
Our final point deals with the aggregator’s inaction to develop integrated pathway
data from their diverse data sources. By standardising gene references and key features
within pathways, we have the ability to integrate similar pathways together. As a result
our integrated pathways are more comprehensive.
Contrasting to prior available methods, researchers can easily use our API to obtain
data for each pathway either from the integrated database or from a specific database
of their choice. This gives researchers a straightforward mechanism for incorporating
pathway information into their microarray analysis.
However, because we use only known biological information in the analysis, it might
suffer from “myopia” as additional new insights without supporting biological basis yet
would be left undiscovered.







Contemporary techniques for analysing biological information have two main deficien-
cies: one, they provide results that are not biologically descriptive and two, results
obtained from one dataset often do not translate easily across a similar but different
dataset. Here we demonstrate the different decision making steps taken to ensure that the
results obtained will provide proper biological analysis to the microarray experiments.
We first explain how we create the foundation to allow biologically descriptive results by
deciding on a proper level of granularity required within the biological pathways of the
unified database. Following which we explain how we arrange genes into their respective
pathway components to take advantage of the gene-gene relationships within pathways.
This is further substantiated with an explanation of statistical testing (which is required
to test for significant pathway components). Finally, these are strung together with a
detailed explanation and example of our algorithm.
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Conclusions
We introduced the concept of a biological “subnetwork” as a suitable degree of granularity
for providing biological descriptive results. This concept was chosen such that it could
provide detailed biological analysis (such as individual differential gene expression),
broad based information (such as the specific topological interactions of these genes
within the subnetworks) and even high-level functional information (such as the original
pathway of the subnetwork).
In addition, we have paid special attention in our algorithmic design (e.g. in the
manner of gene selection, subnetwork scoring, etc) to generate consistent results over
different microarray datasets. These algorithmic details are explained in this chapter
while the performance of it on actual microarray experiments is demonstrated in the next.
6.1 Introduction
As mentioned earlier, most contemporary algorithms (Liu et al., 2007; Pavlidis et al.,
2002; Subramanian et al., 2005) concentrate on finding individual genes or gene pairs
which are differentially expressed. We discussed that using such fine granularity
of information would provide the researchers with long lists of genes/gene lists thus
rendering them ineffective for making biological inferences. Recent advancements have
attempted to solve such issues by using gene sets or gene pathways.
GSEA (Subramanian et al., 2005) uses the strategy of using gene sets to detect entire
groups of genes acting differentially. The research group for GSEA (at Broad Institute)
manually curated their own biological data, placing the genes into individual sets
according to various parameters (eg chromosomal location, biological process, molecular
function, etc). These gene sets are given to the GSEA algorithm which detects the
activated gene sets in the microarray experiment. Because the gene sets are biological
correlated to one another, GSEA can immediately provide biological inferences based on
the functional gene sets.
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The other known solution (used by pathway express (PathwayExpress, 2009), ORA
(Khatri and Draghici, 2005) and FCS (Pavlidis et al., 2002)) is to use known biological
pathways. These pathways are entire groups of genes which are agreed to have a
relationship with one another via consortiums or domain experts. Hence this faces the
immediate issue of deciding which pathways are more accurate because the decision of
which genes should belong to a pathway is still very subjective (Green ML, 2006). We
expect this problem to accentuate as our knowledge of pathways and genes increase.
The main problem of using either gene sets or gene pathways lies in the biological
fact that not all the genes in a set / pathway are affected within a phenotype. Indeed it
is expected that perhaps one portion (say 5-10 genes) of a pathway are affected within a
disease phenotype and a strategy like using entire gene sets or gene pathways result
in such information being missed. In addition, although gene sets or pathways are
being used, these techniques continue to score entire gene sets or pathways via the
individual genes. Hence their technique disregards entirely the relationships between
the genes of the gene set and pathway (Sivachenko et al., 2007; Subramanian et al.,
2005).
Our solution to this is to identify gene regions that are differentially expressed using
connected components. We define the term “subnetwork” or “connected component” as “a
set of genes and relationships where all genes in the connected component are reachable
by all other genes in the (undirected) connected component. Reachability between genes
is established by the existence of an undirected path between the genes of the connected
component.” This is analogous to the definition of “connected components” in classical
graph theory (Cormen et al., 2001). In this thesis, we consider connected components as
a portion of a pathway that fits the above definition. Using connected components as the
level of granularity in analysing our microarray data, we are hence able to:
1. Give detailed information on genes which are differentially expressed.
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2. Provide general analysis and biological inferences on connected components which
are differentially expressed.
3. Directly focus into relevant portions of a pathway.
6.2 Choice of Datasets
Currently, there are two types of microarray experiments, namely spotted microarrays
(which were pioneered by (Eisen and Brown, 1999)) and oligonucleotide microarrays,
invented by (Chee et al., 1996).
The difference is mainly due to the difference in manufacturing of the probes. The
probes of spotted microarrays (oligonucleotides, cDNA, PCR fragments) are synthesised
prior to deposition on the array surface and are then "spotted" onto glass surface.
Probes of oligonucleotide microarrays are short sequences designed to match sequences
of known open reading frames. These sequences are designed to represent single genes
or family of genes.
Numerous studies have been conducted to compare the variation of results across
different platforms and results have been shown to be largely inconclusive. Some of
these studies have shown that the difference in variation is significant (Kuo et al., 2002;
Rogojina et al., 2003; Tan et al., 2003) while others have argued that such differences
are acceptable (Ishii et al., 2000; Yuen et al., 2002).
This phenomena is known as “batch effect” (Lander, 1999) which is often experienced
when experiments are carried out independently (and especially across different plat-
forms). Batch effects can be considered as non-biological experimental variation often
experienced when dealing with multiple batches or platforms of microarray experiments
(Rhodes et al., 2004). This makes analysing datasets across batches difficult. Indeed
attempts have been made to create algorithms to reduce the batch effect by using eigen
vectors or certain forms of mathematical models (Alter et al., 2000; Benito et al., 2004;
Johnson et al., 2007). However require a large number (> 25) of patients within a
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phenotype or these mathematical models fail when some underlying distribution for the
data is not met.
For the datasets we have chosen, most of them are from oligonucleotide Affymetrix
platforms. However we have also chosen experiments where one dataset is from the
oligonucleotide platform while the other is a spotted cDNA microarray. We show that we
can obtain consistent results even across different platforms and types of microarrays.
6.3 Creation of Connected Components from Microarray Data
We create connected components for each dataset by first creating a list of genes that are
significantly expressed and forming connected components from this gene list based on
prior biological knowledge from the integrated database as described in Chapter 4 and
Chapter 5.
6.3.1 Derivation of highly expressed set of genes
We derive our set of highly expressed genes of a phenotype A by first ranking the gene
expression values of each patient of phenotype A. The top n% of genes from each patient
is next selected. Finally we select genes that appear in the top n% of genes for at least
m% percent of the patients of phenotype A. This forms the final list GL of genes which
are considered to be highly expressed within phenotype A.
This technique removes the need to carry out data normalisation because we are
directly ranking genes of each patient according to their expression levels.
Some of the other techniques such as ORA and FCS uses a fixed threshold to obtain
genes which are highly expressed. For instance, we could set the threshold to be ”Mean
+ Std Dev” which implies that all genes with an expression value higher than ”Mean
+ Std Dev” would be considered as significant. However we abandoned this approach
because it introduces additional points of failure. There are multiple techniques put
forth to the simple step of array normalisation (Bilban et al., 2002; Quackenbush, 2002;
Yang et al., 2002) and the techniques to be used might be very subjective. In addition,
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these techniques might yield very different results especially if the experiments are from
different batches and are especially apparent on different platforms.
Hence we put forth our approach of ranking genes and choosing the top n% of genes
common to m% of the patients because this technique is general enough to be applied
in various scenarios. Our motivation for such a technique is to alleviate batch issues by
concentrating on the genes which are expressed relatively higher in the phenotype. The
other alternatives include, for example, carrying out array normalisation, adjusting for
batch effects followed by using the threshold “Mean + Std Dev”. However, we have found
in our experiments that our simpler technique already works well enough.
6.3.2 Derivation of connected components
From this list of top genes, we refer to the biological data repository created in Chapter
4. Using the information within that database, we segregate that list of top genes into
their respective pathways. This is a list of genes considered highly expressed arranged
according to their pathways. We represent genes from the ith pathway as GLi.
The next step involves finding the relationships within the genes of each pathway.
Hence for the ith pathway, we pair up each and every gene within GLi and check with the
data repository if such a gene-gene connection exists within the pathway. (We point out
that we are making a simplification here. Instead of looking at relationships between
genes, example gene g1 activates gene g2, we focus instead only on connections. This
means that regardless of the activating or inhibiting relationships between two genes
within a pathway, we only represent them as gene g1 is connected to gene g2. So we
lose the directional aspect of relationships. (E.g., we will be unable to determine if the
activating relationship between gene g1 and gene g2 is initiated by gene g1 or gene g2.)
Again, for the ith pathway, this gives us a list of gene pairs represented as GPi.
As a final step to obtain the connected components, we first represent each gene within
GLi as a set (with only one member gene). Next we iterate through each gene pair within
GPi. For each gene pair (gene g1 and gene g2), we test if the set containing gene g1 is
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equal to the set containing gene g2. If they are not equal, the sets are merged. Else we
move on to the next gene pair.
This algorithm is made more lucid with the pseudo code and example as shown below:
connected_components(GL)
for each gene g within GL
make-set(g)
end for
for each edge (g1, g2) within GL




This small code takes in the gene set GLi as input. The first loop creates a set from
each gene within the list. The second loop goes through all the individual gene pairs and
merges the gene sets from each gene within the gene pair if they are not equal. Note
that the function set(g1) means a retrieval of the gene set containing the gene g1.
An example, taken from (Cormen et al., 2001) can be seen in Table 6.1. Here we
begin with 10 genes and 7 relationships within the pathway. The first column gives
the different relationships and the first row gives the initial sets, where each set only
contains just a single individual gene. Each new row gives an iteration of the second for
loop in the pseudo code. For instance, in the first iteration, the pair (b, d) is processed.
This merges the sets which contains the gene b and the gene d. Hence the combined set
{b, d}. Take note how the connected components grow during the iterations, giving us
4 different connected components ({a, b, c, d}, {e, f, g}, {h, i} and {j}) at the end of the
routine.
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Table 6.1: Example depicting how connected components are generated. The first row refers
to the starting sets where each gene is in its individual set. The first column refers to the
7 relationships. Each new row shows the processing of the gene sets according to the gene
relationship of the first column. For instance, in the first relationship (b, d), the gene sets b
and d are merged to form the gene set b, d.
{a} {b} {c} {d} {e} {f} {g} {h} {i} {j}
(b,d) {a} {b,d} {c} {e} {f} {g} {h} {i} {j}
(e,g) {a} {b,d} {c} {e,g} {f} {h} {i} {j}
(a,c) {a,c} {b,d} {e,g} {f} {h} {i} {j}
(h,i) {a,c} {b,d} {e,g} {f} {h,i} {j}
(a,b) {a,b,c,d} {e,g} {f} {h,i} {j}
(e,f) {a,b,c,d} {e,f,g} {h,i} {j}
(b,c) {a,b,c,d} {e,f,g} {h,i} {j}
Figure 6.1 shows clearly in a pictorial form how we obtain the connected components
from the microarray experiment and prior biological information.
After obtaining the connected components, we score them with a metric (introduced
later in this chapter). The connected component is scored across both phenotypes
of the experiment. Hence each connected component ends up with two scores, one
for phenotype A and the other for phenotype B. Details of our scoring technique is
elaborated later in Section 6.6.
Our aim then is to devise a statistical test to find components whose score distribution
differs consistently across phenotypes of a disease. The next section provides more
information on how we devise the statistical tests to reject / not reject this hypothesis.
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Figure 6.1: Image depicting how we split the genes GL up to their respective pathways,
match them into e gene pairs and finally connected into their respective cc subnetworks.
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6.4 Statistical Background
Before analysing the different types of hypothesis testing that are available, we first go
through some of the basic technical details of hypothesis testing.
6.4.1 Hypothesis Testing
A hypothesis is a proposed explanation for an observable phenomenon. A null hypothesis
is a specific baseline statement to be tested and it usually implies a state of ”no
difference”. Here, the null hypothesis would probably take the form: that there is no
difference between the means of the expression values across the two phenotype groups.
Hypothesis testing is a scientific process to examine (on the observed phenomenon)
if a hypothesis is plausible or not. In general, hypothesis testing follows the next five
steps.
1. State the null hypothesis
2. Determine the level of significance and whether it is a one-tailed or two-tailed test.
This gives us the thresholds required to reject the null hypothesis.
3. Compute the test statistic and p-value
4. Reject or do not reject the null hypothesis based on the criteria (test size,
significance level, tail test) and the calculated test statistic or p-value.
5. Draw conclusions from rejection / non rejection of the null hypothesis
The classical approach to hypothesis testing computes a test statistic or p value and
compares it with a critical value or significance value. If the test value goes above the
critical value or the p value goes below the significance level, the null hypothesis is
rejected. When rejecting the null hypothesis, two errors may emerge. One where a null
hypothesis is rejected when it is true (Type I errors) and two where we failed to reject
the null hypothesis when it is not true (Type II errors). One of the manners used in
reducing Type I errors is in the proper selection of the level of significance. A level of
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significance at 0.05 means that we are comfortable with the risk of having five incorrect
predictions for every 100 trials. Hence a level of significance at 0.1 would mean that the
test is rather lenient, more apt to produce Type I errors and hence less convincing. A
strict level of significance of 0.01 imply a stricter and more convincing test.
6.4.2 Types of Hypothesis Testing
With this understanding the concepts of hypothesis testing, we analysed the different
techniques available that can be used for hypothesis testing between our experimental
phenotypes. Such means of testing are expounded as below. In addition to explaining
the technical details of each technique, we explain how this technique can be applied in
our context.
6.4.2.1 t-test
t-tests are employed to test the significance of the difference between the means of
two normally distributed populations. If the means of the population differ by a large
amount, it would have a large t-value and normally a low p-value. If the p-value is
sufficiently low, we reject the null hypothesis that the means are equal and conclude that
the means are significantly different. Such tests are typically referred to as "unpaired" or
"independent samples" t-tests, because the two samples being compared are independent
from one another. An example of such an independent test occurs when we are trying
to determine if diabetic subjects are more likely to be obese then in normal non-diabetic
subjects. Conversely, an example of a dependent test occurs when we measure the size of
a patient’s tumour before and after a treatment. If the treatment is effective, we would
expect the tumour to have shrunk after it. Such a statistical test is often called a paired
dependent t-test. Here we are concerned with the former.
In our analysis, we let the statistical null hypothesis be the case where the distribu-
tion of scores for the connected components are similar across the two phenotypes. We
assume that the patients from both phenotypes have the same variance. The number of
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degrees of freedom for either group is the total sample size minus two. This would be












(n1 − 1)S2X1 + (n2 − 1)S2X2
n1 + n2 − 2 (6.2)
SX1X2 is defined as the estimator of the common standard deviation of the two
samples, n1 is the number of samples in the first phenotype and X¯1 is the mean of
the values in the patients of the first phenotype. n2 is correspondingly the number of
samples in the second phenotype and X¯2 is the mean of the values in the patients of the
second phenotype.
Application
For instance, we take the DMD dataset and compare between the patients suffering from
DMD with normal subjects. With a score assigned for each component to each patient.
We create an array of component scores for the DMD patients as well as a corresponding
array of component scores for the normal subjects. We simple apply 6.1 to the two arrays
and calculate the t-score for component. This is repeated for the rest of the connected
components.
6.4.2.2 chi-square
In this section we describe the technical details of Pearson’s chi-square test. This chi-
square test will test the frequency distribution with that of a theoretical distribution
to determine if the distributions between observed frequency distribution differ from
that of the theoretical distribution. A key requirement is the mutual exclusivity of the
individual events. For instance, if a patient appears in the BCR leukemia subtype, that
same patient cannot appear in the MLL leukemia subtype.
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Where n is the number of possible outcomes and the degrees of freedom is equal to
the number of possible outcomes minus 1. However the chi-square test makes a few
assumptions. Firstly, a sample with a sufficiently large size is assumed (to reduce the
probability of committing a Type II error). It is essential that each observation cell
within the contingency table has a size of five or more else the approximation to the
chi-square distribution will not be valid.
Application
Using the DMD dataset, we compare between the patients suffering from DMD with
normal subjects. The normal patients are considered as the expected dataset while the
DMD patients are considered as the observed dataset. A score for each component is
assigned to each patient. We pick a threshold for the score to split the patients into the
2x2 contingency table. An example on how this is done is in Figure 6.2. The threshold
chosen here was the value 5. We have for Phenotype I 4 patients with a component
score greater or equal than 5, 3 patients less than 5. For Phenotype II all patients were
below the threshold of 5. From the creation of this contingency table, we were able to
determine the p-value for each component and determine the components reject the null
hypothesis. Such a rejection would mean that the distribution for that component is
different between the DMD patients and the normal subjects. This is repeated for the
rest of the connected components.
When the chi-square test was deployed unto our experiment, it was able to differ-
entiate the components which behaved differently across the two phenotypes. There
was however an extremely serious issue, which was the size of values within the 2x2
contingency table. Most of the time, the values fell below < 5. Although we understand
that we could have alleviated this problem by using the Yate’s correction, we are aware
Chapter 6. Disease and Drug-Response Pathway Identification — Algorithm 97
Figure 6.2: Illustration of how we create the 2x2 contingency table. The top table refers
to the scores obtained for the patients. P1, P2, .. P8 refers to the identities of individual
patients. I and II refers to the phenotype. By counting the number of patients in the top
table, with score ≤ 5 for phenotype I, we obtain he figure of three in the top left cell of
the contingency table. The reminder of the contingency table can be calculated in a similar
fashion.
of the fact that Yates’ correction tends to overcorrect resulting in a more conservative
result, failing to reject the null hypothesis when it should.
6.4.2.3 One-way ANOVA
The one-way ANOVA is a statistical test of testing if the means of several groups are
all equal. Therefore, it can be considered to be a generalisation of the two-sample t-
test for more than two independent groups. The motivation for using the ANOVA can
be best illustrated with a simple example. For instance, we are testing the response of
three different subtypes of ALL Leukemia, BCR, MLL and E2A. On the surface, one of
the ways to determine if one subtype differs from the other subtype is by performing
a separate t-test between each of the possible pairs of subtypes. For instance, between
BCR and MLL, MLL and E2A and lastly BCR and E2A. Such a strategy is not feasible
because if t-tests are performed on multiple pairs of means, the probability that one
phenotype is classified as "significant" at the 0.05, is substantially greater than 0.05.
Hence the ANOVA was created to address such complications.







(Xij − X¯)2 (6.4)
Where r is the number of rows in the table, c the number of columns and X¯ the grand
mean of the entire table.
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rj(X¯j − X¯)2 (6.5)
Where rj is the number of patients in the jth phenotype and X¯j is the mean of the jth
phenotype. (An example illustrating the calculation of SST and SSTR can be found in
Table 6.2 and Table 6.3.)
Table 6.2: Sample figures to illustrate the Anova algorithm. The figures refers to the








Table 6.3: Sample figures illustrating the calculation of SST and SSTR. The raw expression
values are taken from Table 6.2 and the formulae to calculate the values referred from
Equation 6.4 and Equation 6.5.
Metric BCR MLL E2A Total
Mean 16.6 18.8 19.2 18.2
SST_j 17.2 14.8 18.8 70.4
SSTR_j 12.8 1.8 5.0






(Xij − X¯j)2 (6.6)
Finally we obtain two variance estimates called the MSTR and the MSE. These are
provided in Equation 6.7 and Equation 6.8 respectively. MSTR measures the degree of
the variance between the different phenotypes BCR, MLL and E2A while MSE reflects
the degree of variance of the patients within the same phenotype. Understanding this,
we would expect that if MSTR is larger than MSE, we would be more liable to reject
the null hypothesis. Conversely if MSE is larger than that of MSTR, we would be liable
not to reject the null hypothesis.






N − c (6.8)
where c refers to the number of phenotypes in the experiment and N refers to the total







As mentioned above, the ANOVA method is widely used to determine if the means
of various groups of phenotypes are equal or not. In the experiments conducted
in this thesis, we only compared between two phenotypes. Hence when ANOVA is
executed on just two phenotypes, it effectively reduces to the t-test (ANOVA is merely a
generalisation of the t-test to compare the means between more than two phenotypes)
Therefore there is no difference between using the t-test or ANOVA here. However
should we decide to include more phenotypes into our experiments at a future date,
using the ANOVA test to find test the significance of the differences of means between
> 2 phenotypes would be an extremely viable option.
The remaining two techniques that follow are, strictly speaking, non statistical tests.
However, because these techniques are capable of measuring the response differences
between the two phenotypes, they are considered as potential candidates for testing the
difference in scores for the connected components between the phenotypes.
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6.4.2.4 Entropy
The definition for entropy used is similar to that used by Shannon in information theory.
It is the measure of the uncertainty associated within a variable. For instance, a fair coin
has an entropy of 1 because it is uncertain if the outcome is going to be heads or tails.
Conversely in tossing a biased coin which only turns up heads, it has an entropy rate of






In our context, it is the measure of uncertainty associated with the score of a connected
component has in both phenotypes of the experiment. In the same manner as the chi-
square test, we first split the patients into a 2x2 contingency table. The probability
values were calculated as in Figure 6.3 for each entry of the contingency table (column
wise, according to each phenotype). We chose the option of calculating the entropy value
for each component for each phenotype. The Table 6.4 below how the entropy values
change when the data is in extremes.
Although we are able to determine if the scores are skewed within the phenotypes, we
have no direct way of finding out how the scores in the phenotypes are skewed. Hence
we are unable to differentiate the following two scenarios:
1. Scores in phenotype I are skewed high and the scores in phenotype II are skewed
low (and vice versa)
2. Both the scores in phenotype I and phenotype II are skewed high (or both of them
are skewed low)
The entropy scores for both phenotypes in both scenarios will be low. However the
first scenario is desirable (because it shows a difference in the distribution of scores
between the phenotypes) while the second is not (because they would have the same
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score distribution). Therefore because of this inability to distinguish between these two
important scenarios, this technique for testing may not be very applicable.
Figure 6.3: Illustration of how we create the probability values column wise from the 2x2
contingency table. The top two tables are reproduced from Figure 6.2.
Table 6.4: Table depicting the behaviour of entropy values according to the behaviour of the
phenotype values. For instance, when the values of Phenotype I and Phenotype 2 are skewed,
both their entropy values will be high.
Phenotype 1 Phenotype 2 Entropy 1 Entropy 2
Random Random High High
Random Skewed High Low
Skewed Random Low High
Skewed Skewed Low Low
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6.4.2.5 Gini Coefficient
The gini coefficient is a measure of inequality in a sample group. It is often used in
economics to measure the difference in equality among different income groups. It can
be obtained by dividing the difference between every possible pair of individual – the
”relative mean difference” – by the mean size. With µ defined as the mean size, the gini





j=1 |xi − xj |
2n2µ
(6.11)
The lower the coefficient is, the more equal the distribution is. When the coefficient
is 0, it would mean that there is perfect equality and everyone receives the same
percentage of the total income. When the coefficient is 1, there is perfect inequality
and a single person gets 100% of the income and the remaining (infinite) population
receive none.
Application
In our context, we use the scores obtained in the components as the income figure. Hence
we take the relative mean difference between the component scores to depict the gini
coefficient. Similar to our metric using entropy, we wish to find scenarios where the
component scores are as biased as possible. Meaning that the scores for the phenotype
I are high and the scores the phenotype II are low, and vice versa. Unfortunately this
metric suffers from the same limitations as using the entropy as a metric (see Table 6.5).
Table 6.5: Table depicting the behaviour of gini coefficient values according to the behaviour
of the phenotype values. For instance, when the values of Phenotype I and Phenotype 2 are
uniform, both their entropy values will be low.
Phenotype 1 Phenotype 2 Gini Coeff 1 Gini Coeff 2
Uniform Uniform Low Low
Uniform Skewed Low High
Skewed Uniform High Low
Skewed Skewed High High
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In a parallel fashion, the gini index is unable to differentiate the scenarios as in
Section 6.4.2.4, where the scores for both phenotypes are skewed high (or skewed low)
between the scenario where the scores of phenotype is skewed high, the scores of other
phenotype is skewed low. In this case, the gini coefficient gives a high gini coefficient in
both phenotypes for both scenarios, and there is no direct way of segregating instances
of one scenario from the other.
6.4.2.6 Final selection of hypothesis test: t-test
To reiterate the objective that the test is supposed to serve, it’s main purpose is to easily
select components which gives unfair distribution scores to different phenotypes. If such
components are found, it would mean that the component score is skewed towards some
particular phenotype within the disease and not the other phenotype. The three key
scenarios where this occurs is when:
1. Scores in phenotype I are skewed high and the scores in phenotype II are skewed
low (and vice versa)
2. Scores in phenotype I are skewed high and the scores in phenotype II are uniform
(and vice versa)
3. Scores in phenotype I are skewed low and the scores in phenotype II are uniform
(and vice versa)
Naturally components which exhibit the first characteristic should be given a high
significance value rather than components exhibiting the second and the third scenario.
Given the above criteria, only the t-test, chi-square and ANOVA fulfil them. Both the
entropy and gini coefficient fail as they are unable to sieve out components that fall
under the first criteria. Hence we are left with only the t-test, chi-square and ANOVA.
However, some of the parameters required for the chi-square test are below the required
threshold. Lastly, the metrics ANOVA and t-test are both suitable candidates for the
hypothesis test, fulfilling all three criteria stated. (Indeed ANOVA is a generalization of
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the t-test when applied to more than two variables.) To make our algorithm as general
as possible, it would be best to use the ANOVA as the hypothesis testing method of
choice. However as all our experiments in this thesis only have two phenotypes, both
the ANOVA and t-test produce the same results. Hence, for simplicity, we have used the
t-test for hypothesis testing in this thesis.
6.4.3 Calculation of p-value
The previous section gives an explanation of hypothesis testing and examines the
different types of hypothesis tests that can be used in our experiment. The merits of
each type of test are implemented and we analysed how suitable these hypothesis tests
are. Based on this analysis, we conclude that the t-test is the most suitable choice as
it could meet our requirements of finding components that gave different distributive
scores across the phenotypes.
We form the component scores of both phenotypes, we obtain a t value (based on the
formula for t-test) commonly known as a t-score. This t-score is required to be converted
to a p-value to decide if the component should be significant or not. If its p-value is below
a certain threshold (say 0.05), we would reject the null hypothesis that the mean of the
phenotypes are statistical similar to one another. This means that we have a 5% chance
that component gives a statistically different score between the two phenotypes. There
are two main techniques of obtaining the p-value from the t-score, one by statistical
distribution tables and the other from permuting the empirical data. We describe both
techniques briefly below.
6.4.3.1 Usage of Statistical Tables
In probability and statistics, the t-distribution statistical tables is a probability distri-
bution that is used when estimating the p-value based on the t-score and its sample size
(degrees of freedom). Generally it is bell-shaped, flatter for smaller sample sizes. Hence
getting the p-value from statistical tables involves the straightforward way of reading
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it from a table with the t-score and its corresponding degrees of freedom. The crucial
assumption made here is that getting the p-value from the statistical table assumes
that population follows a normal distribution.
6.4.3.2 Permutation Analysis
The usage of t-test tables requires that the distribution follows a normal distribution.
However if such an assumption is not certain, the other technique of creating the
distribution is by permuting the labels randomly from the experiments and creating
a distribution through such randomisations. This technique is known as permutation
analysis.
Specifically, for each dataset, we permute the phenotype labels, create a new set
of connected components and recompute the scores of this new set of connected
components. This process of permuting the phenotype labels, creating connected
components and lastly recomputing of the scores of the connected components is
repeated for n times. The set of all the randomly generated scores for the connected
components forms the null distribution for dataset. The empirical p-value for each
component can then be calculated relative to this null distribution. More importantly,
the permutation of class labels preserves gene-gene correlations and thus provides
a more biologically reasonable assessment of significance than would be obtained by
permuting genes (Subramanian et al., 2005).
6.4.3.3 Final Selection of Distribution for p-value Calculation: Permutation
Test
Due to the fact that we have no manner of determining if the scores from the connected
components follow a normal distribution, taking the p-values from statistical tables may
result unnecessarily in both Type I and Type II errors. Hence we use the randomisation
process to produce the distribution for each dataset. Using this distribution, we
calculate the p-values for each dataset and obtain the components which are deemed
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as significant. We render components significant if their empirical p-values are less
than 0.05.
6.4.4 Calculation of the p-value from Randomisation Test
From the distributions obtained from the randomisation processes, we have two methods
of calculating the p-value. From the previous section, we have pointed out that during
the randomisation process we randomise the phenotype labels and create randomised
connected components. For each such randomly generated connected component, they
have a corresponding t-score as well as their component size. Hence we have two distinct
distributions. The first is the random distribution of the sizes of such components. The
second is the random distribution of the t-scores of such components. We can either
user both distributions to create our p-value or just the latter distribution to create the
p-value.
6.4.5 Significance of subnetworks
We explain here how the p-value is generated from the permutation tests. There
are two ways to generate this p-value, from (1) the combined distribution of t-scores
and component sizes of the subnetworks or (2) the distribution of the t-scores of the
subnetworks. Both techniques are explained briefly below.
6.4.5.1 Usage of component sizes and t-scores
As mentioned above, one of the methods of obtaining the score from the permutation
process is via both the randomly generated component sizes and their t-scores. Permut-
ing the phenotype labels of the microarray data, and repeating this permutation for n
iterations gives us three distributions: the distribution of the size of the subnetworks
produced using the randomised datasets (Figure 6.4); the distribution of the score of
the subnetworks produced using the randomised datasets (Figure 6.5); and finally a
combined histogram distribution of the size and score of the subnetworks produced using
the randomised datasets (Figure 6.6).
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Figure 6.5 gives the distribution of the scores of the components. The x-axis refers
to the score obtained by the randomly generated components and the y-axis refers
to the percentage of components who has that score. Hence in that figure, we have
approximately 13% of the components with a score of 1, 5% of components with a score
of 2, etc. Figure 6.4 shows the size of the randomly generated components. Here we
find that we have more than 45% of the components with a size of 2 genes, 20% with a
size of 3 genes, etc. The last figure, Figure 6.6 somewhat shows a histogram of these
two distributions. The x-axis is the random component score while the y-axis gives
the random component sizes. The z-axis gives the empirical p-value associated with
such a component score and size. We calculate this p-value by dividing the number
of components with at least size s1 and score s2 by the total number of components
generated by the permutation process.
We can thus find the set of significant subnetworks by calculating the empirical
probability of each subnetwork. Specifically for each subnetwork of size s1 and score
s2, we find (from the histogram) the empirical probability of a subnetwork of at least
s1 genes with score of at least s2 randomly occurring. As an example, Figure 6.4,
Figure 6.5 and Figure 6.6 shows the distribution for dataset on childhood ALL subtype
identification. The blue portion in Figure 6.6 depicts subnetworks whose p-value is below
that of 0.05. This figure clearly shows that the subnetworks which we select (size ≥ 6
genes and score ≥ 2.0) have a p-value small enough ( 0.05) to render such subnetworks
significant.
6.4.5.2 Usage of t-scores
The other technique of obtaining the p-value is to use the scores of the components, based
on the distribution shown in Figure 6.5. Specifically, this means that scores which rank
in the top 5% (with respect to the random distribution) are considered as significant.
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Figure 6.4: Size (number of genes) distribution of the randomly generated subnetworks. The
x-axis refers to the number of genes present within each subnetwork. The y-axis refers to the
percentage of randomly generated subnetworks with that corresponding subnetwork size.
Figure 6.5: Score distribution of the randomly generated subnetworks. The x-axis refers
to the components scores of the randomly generated components. The y-axis refers to the
percentage of randomly generated subnetworks having that component score.
6.4.5.3 Final selection of technique for p-value calculation: Usage of t-scores
After implementing both techniques, we realised that when both component scores and
component sizes are used, components that are large in size but with very low scores
would be deemed as significant. Because of the low score, we realised that they do not
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Figure 6.6: Three dimensional histogram of the size and score distribution of the randomly
generated subnetworks. Note that the portion shaded in blue are the subnetworks rendered
significant.
give good segregation results across the phenotypes and are deemed significant largely
because of their huge size. In contrast, when we used the t-scores to calculate the p-
values, the components deemed significant could obtain better segregation across the
two phenotypes.
6.5 Detailed Approach
This section documents the individual steps of our technique. We first hypothesise that
specific biological processes within pathways are relevant to specific diseases. Thus
our approach concentrates on identifying these biological processes that we termed
“subnetworks”. These subnetworks should be largely the same across independent
datasets of the same disease. Because the probability of such a subnetwork of highly
expressed genes randomly occurring is sufficiently low, we are able to conclude that
these subnetworks have a strong biological relevance with respect to the disease.
Furthermore, such a subnetwork provides intricate information on the interplay and
relationship between the genes, which is advantageous in guiding subsequent research.
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This technique also removes sporadic genes that appear solitary within a biological
pathway (because of their higher possibility of being a false positive).
Only two types of gene-gene relationships are considered: inhibition and activation.
In the example in Figure 6.7, we see the genes ATM, CHK1, CHK2 and MDM2 with the
relationships: ATM activating CHK1, CHK2 and MDM2 inhibiting p53. Thus we define
the term “relationship” between a pair of genes X and Y as a situation where either X
“activates” Y or X “inhibits” Y.
Figure 6.7: Example of the two gene-gene relationships. Left: Type 1 relationship where
gene ATM activates both genes Chk1 and Chk2. Right: Type 2 relationship where gene
MDM2 inhibits gene p53. (Image reproduced from (Soh et al., 2007))
Because of the fine granularity of analysis, the pathway repository must allow
us to easily segregate the original microarray data into its relevant pathways, gene
relationships and subnetworks. Due to the large amount of data, the pathway repository
must also facilitate the development of automated analysis workflows. The repository
therefore is required to have the following characteristics:
• Gene annotations have to be consistent with that in microarray experiments.
• Individual gene relationships within pathways have to be provided.
• The database must have a programmatic interface to access the data.
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However, this set of stringent criteria eliminates contemporary pathway databases
such as Ingenuity (Ingenuity, 1998), BioPax (Kotecha et al., 2008), and GenMapp
(Dahlquist et al., 2002), and we are left with KEGG (Kanehisa and Goto, 2000). However,
KEGG has a number of limitations. Firstly, its collection of pathways is not sufficiently
comprehensive (Green ML, 2006). For example, our analysis in previous sections showed
that 78.8% of pathways in Ingenuity and 64.4% of pathways in Wikipathways are not
contained in KEGG. Secondly, KEGG still uses an old-fashioned SOAP/XML interface.
So we developed PathwayAPI (PathwayAPI, 2009) which offers the combined pathway
information of KEGG, Ingenuity, and Wikipathways along with a modern JSON-based
application programming interface.
Our technique (to be described later) is applied on the disease types listed below with
two different datasets analysed independently for each disease type. The selection of the
two datasets for each disease is made because they were used to compare gene selection
methods in earlier papers (Zhang et al., 2009). In addition, the two datasets for each
disease type are from different platforms, thus providing a more stringent test as they
make it harder for the gene selection algorithms to consistently select the same genes
independently from the two datasets. The disease types of interest include:
• Leukemia: Comparison between leukemia subtypes ALL and AML. Golub (Golub
et al., 1999) uses the Affymetrix HU6800 GeneChip with 47 ALL and 25 AML
patients. Armstrong (Armstrong et al., 2002) uses the Affymetrix HG-U95Av2
GeneChip with 24 ALL patients and 24 AML patients.
• Childhood Acute Lymphoblastic Leukemia (ALL) Subtype: Comparison between
two subtypes of childhood ALL leukemia, E2A-PBX1 and BCR-ABL. Mary (Ross
et al., 2004) uses the Affymetrix HG-U95Av2 GeneChip with 15 BCR-ABL patients
and 27 E2A-PBX1 patients. Yeoh (Yeoh et al., 2002) uses the U133A GeneChip with
15 BCR-ABL patients and 18 E2A-PBX1 patients.
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• Duchenne Muscular Dystrophy (DMD): Comparison between patients suffering
from DMD and normal patients. Haslett (Haslett et al., 2002) uses the Affymetrix
HG-U95Av2 GeneChip while Pescatori (Pescatori et al., 2007) uses HG-U133A
GeneChip. Haslett contains 24 samples from 12 DMD patients and 12 unaffected
controls and Pescatori consists of 36 samples from 22 DMD patients and 14
controls.
• Lung Cancer (Squamous): Comparison between patients suffering from squamous
cell lung carcinomas and normal patients. For lung cancer, the cDNA microarray
data consisted of 13 samples with squamous cell lung carcinomas and five normal
lung specimens (Garber et al., 2001), while the data by Affymetrix human U95A
oligonucleotide arrays consist of 21 squamous cell lung carcinomas and 17 normal
lung specimens (Bhattacharjee et al., 2001).
6.6 Methods
Overview Suppose that the phenotype investigated on is d and the remaining pheno-
types are simply classified as ¬d. We first extract genes which are highly expressed
within this phenotype d from the microarray experiment. This set of genes is next
segregated into their respective subnetworks using apriori biological information from
the pathway repository. This gives us a list of subnetworks cc (whose genes are highly
expressed) within d. A score (depending on the size of the subnetwork and its consistency
among the patients) is next calculated and assigned to each subnetwork. Finally we
estimate the p-value of every single subnetwork within the list and keep those which
are significant. This is elaborated in the following steps:
Step 1: Subnetwork Extraction We create a ranked gene list for each patient
within a phenotype according to the gene expression level of that patient. From this
ranked gene list we extract only the top α% of genes for each patient. This condensed
gene list is referred to as GPi for the ith patient Pi. We next iterate across gene lists GPi
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only for patients of phenotype d, extracting only genes which appear in more than β%
of the patients of phenotype d. This creates a list of genes GL which turns up highly
expressed across most of the patients of phenotype d. Finally, using the programmatic
interface of the database, gene list GL is segregated up the gene list into the respective
subnetworks. In our experiments, α is taken to be 10 and β to be 50.
To segregate GL into the different subnetworks, we first split gene list GL into its
pathways and the gene-gene relationships within these pathways. (We highlight that a
gene is allowed to appear in more than one pathway.) Next by treating each gene as a
vertex and each gene-gene relationship as an edge, we can easily locate the connected
components (subnetworks) formed by these edges (gene-gene relationships) and vertices
(genes). This process is illustrated in Figure 6.1.
Step 2: Subnetwork Scoring We assign a score vector Sspsp,d with respect to
phenotype d to each subnetwork sp within cc according to Equation 6.12.
Sspsp,d = 〈Sccsp,1,d, Sccsp,2,d, ..., Sccsp,n,d〉 (6.12)
Where n is the number of patients in phenotype d. The formula Sccsp,i,d for the ith





Sgsp,j,d refers to the score of the jth gene (say, gene x) in the subnetwork sp for
phenotype d. (This score Sgsp,j,d is given by Equation 6.14) and is simply given by:
Sgsp,j,d = k/n (6.14)
Here, k is the number of patients of phenotype d who have both gene x highly
expressed (top α%) and n is the total number of patients of phenotype d. The entire
Step 2 is repeated for the other disease phenotype ¬d, giving us the score vectors, Sspsp,d
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and Sspsp,¬d for the same set of connected components. The t-test is finally calculated
between these two vectors, creating a final score for each subnetwork within cc.
Step 3: Subnetwork Significance We repeat Steps 1 and 2 for all the phenotypes
in the dataset to extract a list of subnetworks SN. The significance of the observed
subnetworks is estimated by randomly permuting the phenotypes labels, re-extracting
the subnetworks and recomputing their scores. This generates a null distribution for the
score and size of the subnetworks. The p-value of each subnetwork is then calculated
relative to this null distribution.
A Randomly swap the phenotype labels of the patients, recreating the subnetworks
and recalculating their scores.
B Repeat [A] for 1,000 permutations. This creates a two dimensional histogram of
the scores and sizes of the subnetworks.
C Estimate the nominal p-value of each subnetwork by using the histogram created
in point [B].
Finally, we consider subnetworks whose p-value was sufficiently small (≤ 0.05) to
be significant. Doing so would provide us with an independent set of significant
subnetworks SN for each dataset. Using our algorithm, we have managed to show that
we are able to obtain consistent significant subnetworks across different datasets of the
same disease. This is illustrated in further details in the next chapter.
6.7 Example
We present results here based on the DMD datasets from (Pescatori et al., 2007) and
(Haslett et al., 2002) to illustrate the working of our algorithm.
Running the algorithm concurrently on both datasets and comparing the significant
components across the datasets, we saw an overlap percentage of 58.33% (7 overlapping
components) between the two datasets. Overlap of the genes within the components
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was computed and an overlap percentage value of 69.23% was obtained. More detailed
comparisons with the other algorithms will be presented in the following chapter.
How we obtain the significant components is as follows: In the Pescatori dataset,
we have 22 DMD patients and 14 normal patients. Our first objective is to locate the
connected components that have a majority of their genes highly ranked in the majority
of the DMD patients.
We first rank the genes of each patient according to their expression values. The top
10% of the genes is next extracted from the ranked list of each DMD patient. From the
top 10% gene list from each DMD patient, we select only the genes which appear in more
than 50% of the patients. This provides us with a list of genes that are generally more
highly expressed among the DMD phenotype for the Pescatori dataset. We constructed
a set of connected components from this list of genes and our aggregated database.
We next calculated a score of each connected component from each patient (from both
phenotypes) according to the formula provided in 6.12. Finally we calculated the p-value
of each connected component by using a t-test of the connected component scores across
both the DMD and Normal phenotype patients. Existance of a connected component
with a high t-test value suggests that there is a significant difference between the DMD
and Normal patients within the datasets, thus making that particular component more
significant.
The p-value is calculated via a randomisation process similar to that reported
previously (Subramanian et al., 2005). Basically, using the data from the Pescatori
dataset, we performed a random assignment of the 22 DMD and 14 normal phenotypes.
With this new set of data with randomised phenotypes, we repeated the procedure for
calculation of the t-test score. This involved the ranking of genes, obtaining the genes
which are significant, recreating the subnetworks once again and finally calculating
a t-test score for each subnetwork. This randomisation process is repeated for 1000
permutations, producing a distribution of randomly generated connected components
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with their relevant t-scores. This distribution is used to calculate the p-value of each
of the connected components of the original Pescatori dataset. From this original set
of components, we find the components with scores higher than 95% of the component
scores from the randomised distribution. These components are rendered as significant
components.







We compare our technique with several popular methods of microarray analysis such
as SAM (Tusher et al., 2001), t-test (Cui et al., 2005) and GSEA (Subramanian et al.,
2005) in this chapter. This comparison is made on four different disease types and
eight different datasets (Leukemia (Armstrong et al., 2002; Golub et al., 1999), Leukemia
Subtypes (Ross et al., 2004; Yeoh et al., 2002), DMD (Haslett et al., 2002; Pescatori et al.,
2007), Lung Cancer (Bhattacharjee et al., 2001; Garber et al., 2001)). We make our
comparisons by finding:
1. The significant pathway overlap between datasets of the same disease
2. The significant gene overlap between datasets of the same disease
3. The size of subnetworks obtained from our technique compared with the size of
subnetworks obtained from the t-test
4. Consistency of significant genes with genes obtained from t-test
5. Biological relevance of sample subnetworks
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Conclusions
We illustrate that we consistently outperform the other techniques in our experiments.
Specifically we achieved,
1. a significant pathway overlap of 47.63% to 83.33% as compares to GSEA (0% to
55.6%).
2. a significant gene overlap of 51.18% to 93.01% as compares to that of the GSEA
(2.38% to 28.90%), t-test (49.60% to 73.01%) or SAM (49.96% to 81.25%).
3. subnetworks of a larger size (5 to 16 genes) as compares to t-test (2 to 5 genes).
4. subnetworks whose genes are also marked as significant by the t-test
5. biological validation of two sample subnetworks by existing biological literature.
This clearly demonstrates that our technique generates significant subnetworks and
genes that are more consistent across datasets compared to the other popular methods
available (GSEA, t-test and SAM). The large size of subnetworks which we generate
indicates that they are generally more biologically significant (less likely to be spurious).
To validate our results, we show that most of our genes from the generated subnetworks
have also been considered significant by the t-test. In addition, we have chosen two sample
subnetworks and validated them with references from biological literature. This shows
that our algorithm is capable of generating descriptive biologically conclusions.
7.1 Introduction
To demonstrate the utility of our algorithm, we employ it to analyse the differential
response between phenotypes of a few diseases. This is employed independently across
two different datasets of the same disease.
To show that the output connected components from both datasets of the same disease
are consistent, we first analyse the overlap of significant connected components over both
datasets of the same disease. A high level of overlap means that the results are more
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biologically significant, being more consistent over datasets of the same diseases. This is
compared with GSEA where we ran the GSEA algorithm over both datasets of the same
disease, found the significant pathways from each dataset and calculated the pathway
consistency overlap across the two datasets for each disease.
After analysing the overlap on connected components / pathways, we concentrate on
analysing the overlap of significant genes from the two datasets of the same disease. A
gene list is formed by taking the genes within all the significant components of each
dataset. Next we calculate the percentage overlap within the gene list across both
datasets of the same disease. This gene percentage overlap is compared with three other
algorithms: t-test, SAM and GSEA.
With the significant genes (obtained from the t-test) from the two datasets of the each
disease, we make two further comparisons:
1. We create connected components from this list of genes to compare the sizes of
connected components obtained from the t-test with that from our technique.
The purpose is to find out which technique generates larger (and possibly more
significant) components.
2. We analyse if the genes found within our connected components are also contained
within this list of significant genes. This test acts as an independent check that
genes obtained from our algorithm have also been confirmed to be significant by
another algorithm.
With the connected components obtained from our technique, we score them using
our formula in Equation 6.12 and show a few sample histograms depicting the scores
for the connected components. These sample histograms differentiate the patients of the
different phenotypes for the different diseases.
For ease of explanation, the results for our technique are named under the acronym
SCC, which simply stands for “significant connected components”
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7.2 Significant Subnetworks Overlap
For each disease, two lists of significant subnetworks are identified by applying our
technique independently on the two different datasets for the disease. We next calculate
the percentage overlap between the two lists of significant subnetworks.
This result is compared with another algorithm that extracts significant gene lists
from microarray data, GSEA. The individual pathways from the database (PathwayAPI)
and their associated genes are used as input gene sets for GSEA. Hence running GSEA
with this database of pathways gives us a selected set of pathways deemed as significant
by GSEA. GSEA is applied to both datasets of the same disease. For each dataset, we
obtain a list of pathways significantly expressed and remove the pathways whose FDR
q-value falls below 0.25. Finally we calculate the percentage intersection between the
remaining pathways within these two lists.
Results indicate that our technique (as compared to GSEA) consistently gives a higher
percentage overlap for different datasets of the same disease. Here, our technique
obtained a high overlap percentage for these datasets (47.63% to 83.33%). As an example
from Table 7.1, the percentage overlap of pathways in determining the ALL Subtype
(second row in that table) in SCC is 47.63% while that for GSEA is 23.1%. The full results
can be observed in Table 7.1. Table 7.2 shows the number of overlapping significant
pathways for each disease type.
Table 7.1: Table showing the percentage overlap significant pathways between the datasets.
Each row refers to a separate disease (as indicated in the first column). Each disease is tested
against two datasets depicted in the second and third column. The overlap percentages refer
to the pathway overlaps obtained from running SCC (column 4) and GSEA (column 5).
Disease Dataset 1 Dataset 2 SCC GSEA
Leukemia Golub Armstrong 83.33% 0%
ALL Subtype Ross Yeoh 47.63% 23.1%
DMD Haslett Pescatori 58.33% 55.6%
Lung Bhattacharjee Garber 90.90% 0%
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Table 7.2: Table showing the number of significant overlapping pathways between the
significant pathways. Each row refers to a separate disease (as indicated in the first column).
Each disease is tested against two datasets depicted in the second and third column. The
overlapping figures refer to the pathway overlaps obtained from running SCC (column 4) and
GSEA (column 5).
Disease Dataset 1 Dataset 2 SCC GSEA
Leukemia Golub Armstrong 20 0
ALL Subtype Ross Yeoh 10 6
DMD Haslett Pescatori 7 10
Lung Bhattacharjee Garber 9 0
This high level of overlap between different datasets means that our technique is able
to obtain more consistent results across datasets of the same disease. Such consistency
may indicate that our algorithm is able to obtain results that are more significant
because of our technique and granularity of the usage of biological data within our
analysis.
We obtain a low result overlap from GSEA possibly because the pathways from
PathwayApi are very large and GSEA relies on a large portion of a pathway to exhibit
a correlated change. Hence when only a subset of a pathway demonstrates differential
expression, GSEA may be unable to pick this up. We verified this hypothesis by feeding
into GSEA subnetworks that we found from our algorithm into the leukemia datasets.
Indeed, the overlap percentage improved. The following subnetworks were found to be
significant and overlapping.
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7.3 Significant Genes Overlap
From the two lists of significant subnetworks for each disease, we extract two lists
of genes that occur in the two corresponding lists of subnetworks and find out the
percentage overlap of these genes that are present. This percentage is defined as the
number of overlapped genes divided by the number of genes in the smaller list (We term
the number of genes in the smaller list as γ).
We carry out the t-test on our datasets by calculating a p-value for each gene and only
selecting the genes which has a p-value of less than 0.05. We next take only the top γ
genes that are significant. Following which we evaluate the percentage overlap between
the two lists of top γ genes from each dataset.
For GSEA, we obtain the significant set of genes by first selecting the leading edge
set of genes from the well expressed pathways for each dataset. We obtain two such
lists for each dataset and calculate the percentage overlap between these two lists (The
percentage overlap is simply defined as γδ where γ is the number of overlapping genes
between the two lists and δ is the size of the smaller gene list).
The results, shown in Table 7.4, Table 7.5 and Table 7.6 show that the gene overlap
obtained from GSEA, t-test and SAM are consistently and significantly lower (2.38% to
28.90% for GSEA, 49.60% to 73.01% for t-test, 49.96% to 81.25% for SAM) as compared
to that of our technique (51.18% to 93.01%).
In Table 7.5 and Table 7.6, there are two columns with the same labels. Specifically in
Table 7.5 there are two headers with the same column “t-test” and in Table 7.6 are two
columns with the same column label “SAM”. Notice however that the number of genes
being compared are different. For example in Table 7.5, for the first disease leukemia,
we compare the gene overlap in the first 1239 genes in the first column for the t-test and
84 genes in the second column for the t-test. We obtain the comparison figure of 1239
genes by counting the number of genes which are significant by the t-test (p-value <
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0.05). The other comparison figure of 84 genes is obtained by counting the total number
of genes present within our subnetworks obtained for the leukemia datasets.
We point out that the gene overlap for SAM is better in some instances. This is
probably due to the stringent criteria that we have for some of the parameters. For
instance, we select the top n% of genes that appear in m% of patients of a phenotype.
We have used the values of 10 for n and 50 for m. If these values are relaxed, it would
probably result in more genes being selected and provide a better overlap value.
Table 7.4: Table showing the number and percentage of significant overlapping genes. γ
refers to the number of genes compared against and is the number of unique genes within all
the significant connected components of the disease datasets. The gene overlap refers to the
percentage gene overlap between the two datasets of a disease for SCC (column 3) and GSEA
(column 4).
SCC GSEA
Leukemia Num Genes γ =84 84
Genes overlap 91.30% 2.38%
ALL Subtype Num Genes γ =75 75
Genes overlap 93.01% 4.0%
DMD Num Genes γ =45 45
Genes overlap 69.23% 28.9%
Lung Num Genes γ =65 65
Genes overlap 51.18% 4.0%
Table 7.5: Table showing the number and percentage of significant overlapping genes. γ
refers to the number of genes compared against and is the number of unique genes within all
the significant connected components of the disease datasets. The gene overlap refers to the
percentage gene overlap between the two datasets of a disease for SCC (column 3) and t-test
(column 4).
SCC t-test t-test
Leukemia Num Genes δ =84 1239 84
Genes overlap 91.30% 73.01% 14.29%
ALL Subtype Num Genes δ =75 1072 75
Genes overlap 93.01% 60.20% 57.33%
DMD Num Genes δ =45 1319 45
Genes overlap 69.23% 49.60% 20.00%
Lung Num Genes δ =65 2091 65
Genes overlap 51.18% 65.61 26.16%
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Table 7.6: Table showing the number and percentage of significant overlapping genes. γ
refers to the number of genes compared against and is the number of unique genes within all
the significant connected components of the disease datasets. The gene overlap refers to the
percentage gene overlap between the two datasets of a disease for SSP (column 3) and SAM
(column 4).
SCC SAM SAM
Leukemia Num Genes δ =84 1305 84
Genes overlap 91.30% 49.96% 22.62%
ALL Subtype Num Genes δ =75 464 75
Genes overlap 93.01% 81.25% 49.33%
DMD Num Genes δ =45 126 45
Genes overlap 69.23% 76.98% 42.22%
Lung Num Genes δ =65 966 65
Genes overlap 51.18% 65.61 24.62%
7.4 Size of subnetworks obtained from t-test
This section shows that the size of the subnetworks we obtain using our algorithm is
significantly larger than those we would obtain from the t-test algorithm. Naturally
the larger the components are, the more biological inferences can be drawn from the
microarray data and the more significant they are likely to be. We first obtain a ranked
gene list for each dataset using the t-test algorithm. We therefore obtain two ranked
gene lists for each disease i. Assuming once again that the total number of genes present
within the significant subnetworks for a disease i is δ_i, we extract the top δ_i genes
common to both ranked gene lists of each disease i. Lastly, we calculate the size of
the subnetworks formed by this top δ_i genes. The results in Table 7.7 show that the
subnetworks obtained are smaller in size (≤ 5 genes) and hence less interesting and
significant.
7.5 Validity of Subpathway Genes
To check the validity of the connected components selected, we compare the genes are
present within each connected component with those deemed significant by the t-test. A
high percentage would mean that we are able to capture connected components which
are highly consistent to established methods such as the t-test. The tables below, Table
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Table 7.7: Table comparing the size of the subnetworks obtained from the t-test and
from SCC. The first column shows the disease that is being considered and the second
column shows the number of genes used to create the subnetworks. The third column
(which comprises additionally of 4 subcolumns) depicts the number of genes present within
each subnetwork for the t-test. Similarly the fourth column depicts the number of genes
present within each subnetwork for SCC. So for instance in the leukemia dataset, we have
8 subnetworks with size 2 genes, 1 subnetwork with size 3 genes for the t-test. For SCC, we
have 2 subnetworks with size 5 genes, 3 subnetworks with size 6 genes, 2 subnetworks with
size 7 genes and 1 subnetwork with a size of ≥ 8 genes
Disease γ Num genes (t-test) Num genes (SCC)
2 3 4 5 5 6 7 ≥ 8
Leukemia 84 8 1 0 0 2 3 2 1
Subtype 75 5 1 1 1 1 0 1 6
DMD 45 3 1 0 0 1 0 0 5
Lung 65 3 2 1 0 5 3 0 1
Table 7.8: Table depicting the percentage of genes from connected components which are also
significant for the t-test. The first column depicts the name of the subnetwork considered.
The second column depicts the percentage of genes from that subnetwork which are also






leukemia_Regulation of actin cytoskeleton_RAC1 57.14%
leukemia_Proteasome Degradation_UBC 100.00%
leukemia_Regulation of Actin Cytoskeleton_RAC1 57.14%
leukemia_B Cell_NFKB1 80.00%
leukemia_Regulation of actin cytoskeleton_CSK 75.00%
leukemia_B Cell Receptor Signaling_POU2F2 75.00%
leukemia_IL6 Signaling_IL8 75.00%
leukemia_Focal Adhesion_ACTB 100.00%
7.8 to Table 7.11 show the different components found significant within their respective
disease sets. The corresponding percentage depicts the percentage of genes present
within the connected component which is also significant by the t-test (taken with a p-
value threshold of 0.05). We can observe from the tables that the bulk of the components
have a high consistency percentage, falling between 70% to 100%.
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Table 7.9: Table depicting the percentage of genes from connected components which are also
significant for the t-test. The first column depicts the name of the subnetwork considered.
The second column depicts the percentage of genes from that subnetwork which are also
deemed significant for the t-test. (Leukemia Subtype datasets (Ross et al., 2004; Yeoh et al.,
2002))
Component name Percentage
MLLBCR_Fatty acid metabolism_ACAA1 28.57%
MLLBCR_Valine, leucine and isoleucine degradation_HSD17B10 40.00%
MLLBCR_B Cell_BLNK 72.73%
MLLBCR_Valine, leucine and isoleucine degradation_HSD17B10 33.33%
MLLBCR_B cell receptor signaling pathway_BLNK 72.73%
MLLBCR_Acute myeloid leukemia_FLT3 44.44%
BCR_Chronic myeloid leukemia_ABL1 75.00%
BCR_Fc Epsilon RI Signaling_PIK3C2B 70.00%
BCR_T Cell Receptor Signaling Pathway_RASA1 44.44%
Table 7.10: Table depicting the percentage of genes from connected components which
are also significant for the t-test. The first column depicts the name of the subnetwork
considered. The second column depicts the percentage of genes from that subnetwork which







DMD_Leukocyte transendothelial migration_ACTB 83.33%
DMD_Actin Cytoskeleton Signaling_MYL9 78.57%
DMD_Calcium signaling pathway_CALM1 80.00%
Table 7.11: Table depicting the percentage of genes from connected components which
are also significant for the t-test. The first column depicts the name of the subnetwork
considered. The second column depicts the percentage of genes from that subnetwork which
are also deemed significant for the t-test. (Lung datasets (Bhattacharjee et al., 2001; Garber
et al., 2001))
Component name Percentage






SCC_Natural killer cell mediated cytotoxicity_TNFSF10 60.00%
SCC_Insulin Recpetor Signaling_AKT3 100.00%
SCC_Glycogen Metabolism_PYGM 60.00%
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7.6 Histograms of Connected Components
Finally, we show the histogram of the distributions of the different connected compo-
nents. The y-axis of the histograms depict the number of patients while the x-axis
depicts the percentage of genes that are high in that segment. We will first show a
few sample histograms (Figure 7.1) where we are able to obtain nice histograms which
clearly show the difference between the phenotypes of the various diseases. The rest of
the histograms are included in the Appendix for the interested reader’s reference.
Figure 7.1: Sample histograms depicting the scores obtained from the connected
components. The top two graphs, refer to the 097_304_1_Golub_AML connected component.
The left graph shows the scores obtained from the Armstrong microarray experiment and
the right from the Golub microarray experiment. The x-axis refers to the score assigned and
the y-axis refers to the number of patients with that score. The dark colored bars refers to
the patients suffering from AML while the light colored bars refers to patients suffering from
ALL. For the DMD graphs, dark colored bars refers to normal control patients while light
colored bars refer to patients suffering from DMD.
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7.7 Biological Relevance of Sample Subnetworks
Two small sample subnetworks are chosen here to show the biological significance of the
results obtained. The first which we describe below in Figure 7.2 is generated from the
leukemia dataset. The genes within this subnetwork are very substantially supported
by literature with respect to their role in leukemia. For instance, the gene RAC (which
regulate a diverse array of cellular events) is referenced in (Krishna and LeDoux, 2006;
Wang et al., 2009) as having an effect on leukemia. Other genes within the network are
Rhoa (regulates the actin cytoskeleton in formation of stress fibers) in (Booden et al.,
2002; Kristelly et al., 2004), Vav1 (plays a major role in development and activation
of T-cell and B-cell blood cells) in (Katzav, 2007) and IQGAP (regulates cell adhesion,
morphology and motility) in (Juliana et al., 2006).
Figure 7.2: A sample pathway component from leukemia dataset (Armstrong et al., 2002;
Golub et al., 1999).
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The next subnetwork shown in Figure 7.3 is generated from the DMD disease
datasets, and is taken from the Apoptosis pathway. Results from our algorithm indicated
that the genes groups MYL and MYH are significantly differentiately expressed between
the DMD patients and the normal patients. MYH (myosin, heavy chain) and MYL
(myosin, light chain) are known to be major gene groups involved in release of
mechanical energy allowing muscles to contract. These genes are heavily quoted in
literature with regard to their involvement in the disease DMD: MYH3 and MYH8
(Haslett et al., 2002), MYH6 (Balagopal et al., 2006), MYH7 (Baker et al., 2006), MYL1,
MYL2, MYL3, MYL4, MYL5, MYL6 and MYL9 (Balagopal et al., 2006). In addition, the
gene titin which was identified. Titin is a gene which encodes a large protein of the spinal
skeletal muscles and its mutation is widely found to occur in various types of muscular
dystropy (Garvey et al., 2002; Gerull et al., 2002; Hackman et al., 2002; Itoh-Satoh et al.,
2002).
Chapter 7. Disease and Drug-Response Pathway Identification — Results 130
Figure 7.3: A sample pathway component from DMD dataset (Haslett et al., 2002; Pescatori
et al., 2007).




Microarray experiments are crucial because they measure the behaviour of individual
genes with respect to diseases or treatments. Results from these experiments are
heavily scrutinised to obtain biological insights into the occurrence of diseases or the
effectiveness of certain types of treatments.
In order to provide more indepth analysis to experiments, contemporary algorithms
have incorporated biological information into their analysis so that the analysis can
be more descriptive and hopefully useful to the researchers. Our techniques have
taken this approach one step further. Firstly, we no longer consider prior biological
knowledge as a separate aspect of microarray analysis. Rather, we take into account
the integrity of the biological information that is being provided into the algorithm
for analysis. Secondly, our algorithm uses both the gene-gene interaction information
and pathway information in our analysis. Because of these two enhancements, we are
able to generate subnetworks in real-time according to the responses of the microarray
experiments. These contributions helps us avoid some of the potential caveats present
within microarray experiments.
Our first rigorous step (as explained in Chapter 3) of demonstrating qualitatively
the huge inconsistencies within current databases is already a non-trivial contribution.
This step is crucial because it demonstrates the lack of coherency (qualitatively results
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seen in Chapter 5) between microarray analysis if different databases are to be used.
Hence we created our own database by combining the information from several other
well established biological databases. This ensures that the prior biological information
going into the algorithm is generally agreed upon among the databases and hence we
can expect greater consistency in the results.
Referencing our chapter about algorithmic design (chapter 6), we again distinct
ourselves from the algorithms such as GSEA and NEA (Sivachenko et al., 2007) by
using both gene-gene relationships and pathway information. The paper by (He and
Zhang, 2006) pointed out that such hubs in gene-gene interaction networks correspond
to essential genes because they have a higher probability of involvement in essential
gene-gene interactions. Therefore the usage of gene-gene relationships provides us with
information on how genes affect one another and pathway information organises such
relational information within their relevant biological processes. In contrast, GSEA only
uses gene sets (akin to our pathway information), hence losing crucial information on the
individual processes occurring between genes. In general, not all genes in a gene set are
connected to each other (and rightfully so), GSEA might rank gene sets as significant
although the number interactions between the proteins within each gene set is weak. In
addition, other processing steps are required to decipher how genes within a gene set
interact with one another. In addition, GSEA might also rank a gene set as insignificant
if the gene set is very big and most of the genes are not differentially expressed, even
when there is a path within the large set that is differentially expressed. This happens
when a portion of the gene set is significantly differentially expressed, but the rest of the
genes are not. Thus even though that particular portion of the gene set is biologically
significant, this will not be indicated out by GSEA.
We are certainly not the first to integrate gene-expression data with gene-gene
relationships. GNEA (Liu et al., 2007) is one such example. GNEA uses a global protein-
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protein interaction network, finds a subnetwork within this global interaction network
and compares this subnetwork within gene sets to find out the significant gene sets.
However in creating a single global biological interaction network, it makes the
biological assumption that the local behaviour of proteins can be translated in a similar
fashion globally and that gene expression levels are in a tight correspondence to protein
levels (which is not generally true). A similar issue is raised in (Sivachenko et al., 2007)
where the authors argued that proteins which are very well connected have an extremely
high chance of obtaining a low p-value and being ranked as significant. Because of
the high connectivity of such proteins, they are liable to be involved in various disjoint
biological processes, leading to the error of combining independent subnetworks through
these proteins. To prevent such scenarios, we instead implemented our algorithm via
identifying localised gene-gene subnetworks within pathways.
In addition, we show in Chapter 7 that our technique generates significant subnet-
works and genes that are more consistent across datasets compared to the other popular
methods available (GSEA, t-test and SAM). The large size of subnetworks which we
generate indicates that they are generally more biologically significant (less likely to be
spurious). To validate our results, we show that most of our genes from the generated
subnetworks have also been considered significant by the t-test. In addition, we have
chosen two sample subnetworks and validated them with references from biological
literature. This shows that our algorithm is capable of generating descriptive biologically
conclusions.
Our final contribution lies in our ability to create connected components (of known
pathways) in real time based on microarray data. This allows us to obtain connected
components according to the microarray data. GSEA uses fixed gene sets and determines
if these gene sets are significant or not. GNEA first finds subnetworks from a global PPI
(protein protein interaction) network. The GNEA next carries out a statistical test on
fixed gene sets, to determine the individual gene set has a significant proportion of genes
Chapter 8. Conclusions 134
within this subnetwork. Hence these techniques assume that a gene set is significant
only if it has a substantial proportion of its genes significant. This assumption might not
be valid because there are instances where only part of a gene set becomes significant,
and it would probably go noticed if the rest of the genes are unaffected. Our ability to
create connected components based on the microarray data of the phenotypes ensures
that we have sufficient granularity to capture portions of pathways or gene sets are
affected.
With reference to Chapter 1, these contributions enable us to successfully make
consistent biological inferences from microarray experiments and prior biological infor-
mation.
8.2 Future Work
Biologically descriptive analysis of microarrays is currently an active of research,
providing many opportunities for novel ideas. While this thesis has contributed some
new concepts in this area, it contains its own shortfalls and there remains many
interesting issues that necessitate further research.
8.2.1 Building an automated tool
To demonstrate the validity of our algorithm, we have chosen to use only two datasets of
various diseases rather digging in depth into a single disease but across many datasets.
Though this has shown that we are able to obtain significant results across two datasets
of the same disease, we may have achieved additional interesting biological results if
we were able to find consistent results using further datasets from the same disease. If
the biological conclusions from a single disease are consistently significant across all the
other datasets, it is likely that this has biological significance.
To carry out such large-scale analysis, it will require us extending the algorithm
towards building a more automated tool. This tool will require us to revise the following
components:
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1. Microarray input formats The current method of accepting DNA microarray inputs
into the algorithm is still very manual. The extension will allow the algorithm to
accept the microarray data with its annotation information and automatically link
it back to the biological pathway inputs.
2. Biological input formats Only biological data from PathwayAPI is accepted cur-
rently. One of the extension will be to extend this to other biological formats like
SBML, BioPaX and SGML. This will allow the tool to be more pervasive and not be
tied down to any particular biological repository.
3. Statistical processing For statistical processing, we will have to replace the
hypothesis test with ANOVA to allow connected components from multiple datasets
of the same disease to be tested at the same time.
These improvements will allow us to carry out wide-ranging and large scale studies
within GEO and other important databases, allowing us to detect significant subnet-
works that are consistent across databases. If these subnetworks are significant across
more datasets, they will provide further support for a pathophysiological role and/or
additional clinical insight for the researcher.
8.2.2 RNA Seq
An extension to use RNA-Seq as the choice of experimental input is possible. However
the design of the algorithm will have to cater to the vast amounts of additional data when
RNA-Seq is being used and there being a greater level of biological granularity within
RNA-Seq experiments. Together with a biological database that supports this level of
granularity, the algorithm will be able to increase the amount of descriptive information
that the algorithm will be able to provide (without a large change in the fundamental
algorithm).
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8.2.3 Over-reliance on biological information
The main conceptual shortfall of the algorithm involves our reliance on biological
data. As pointed out also in (Sivachenko et al., 2007), there are two scenarios where
our solution will find it challenging to find any biologically significant results. One
such situation occurs when the biological information available is not sufficiently
comprehensive. Naturally when the information is not comprehensive, the connected
components created will not be sufficiently large / comprehensive to be significant and
hence will be unable to provide proper biological descriptions. The second situation
occurs when the biological information provided is inaccurate. In such cases, we will
create the wrong components within the pathways and hence draw incorrect conclusions
from the results. We understand such a problem and have tried to alleviate such
issues by creating our own integrated biological database. However we realise that
such issues are inevitable and there is always a probability of it occurring. Naturally in
such scenarios, the system must at least be able to differentiate the difference between
the situation where “no significant results are found because of a lack of biological a
priori information” and “no significant results are found because of a lack of correlating
microarray data”.
8.2.4 Pairwise connections within components
In addition, although biological information is being integrated into the analysis, we
are utilising gene pairwise connections within components instead of their pairwise
relationships (For instance, instead of taking into account the relationship p53 activates
MDM2 or MDM2 inhibits p53, we merely use the connection between the two genes,
simplifying their relationship to one that p53 is connected to MDM2). This simplification
greatly reduces the granularity of our analysis. For instance, if in the scenario where
both p53 and MDM2 are activated, we could deduced that the relationship “p53 activates
MDM2” is significant and in the scenario where only MDM2 is activated, we could
deduce that “MDM2 inhibits p53” is significant. However with our simplification, we
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can only deduce that the connected between p53 and MDM2 is significant in the former
scenario and we can deduce nothing significant in the second scenario.
Finally, although we have used our best efforts to ensure a professional standard in all
our experimental studies, there are still some limitations of the project due to its scale.
For instance, the biological repository we created came from only three independent
pathway repositories. Although the number of pathways combined together is already
considered substantial (as most analysis only use a single database), we understand that
the more databases we include in our study, the more complete the information we would
hold and the more complete the study would be.
8.3 Discussions
8.3.1 Comparison with previous techniques
We are able to perform better than GSEA because we have managed to concentrate on
a more focused granularity, finding connected components which are significant and not
entire pathways. This gives us an extremely good size for biological analysis because
it is large enough to make proper biological inferences, yet small enough such that the
possibility of false positives and false negatives is kept as low as possible. This especially
goes true in the future as lines between pathways become blurred (deciding which genes
should be allowed in which pathways is already a subjective issue). In addition, as more
data gets available, pathways tend to increase in size as well and not all genes within
it are actually relevant to the analysis. (We have tried running the data on Pathway
Express (PathwayExpress, 2009) but unfortunately were unable to obtain any results.
This is probably due to the size of the data as Pathway Express works better on smaller
datasets.)
8.3.2 Irregularity of microarray experiments
Though microarray experiments have seen vast improvements over the last few years,
they are still relatively rudimentary as compared to the exact binary computational
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systems that we are so used to. For instance, it is a known fact that there is a natural
fluctuation in the expression level of genes within a cell. This natural fluctuation may
cause the natural ranges of expression of the same gene from different cell phenotypes
(eg normal vs disease) to overlap. A sudden rise of the expression level of a gene therefore
may not suggest the cell phenotype. To alleviate the impact of such scenarios, our
solution was to chose only genes who appear highly expressed in more than 50% of the
patients of a phenotype.
8.3.3 Metrics Used
The final version of our algorithm used the t-test to find components which are activated
more in one component and less in the other component. Other than the t-test we
had tested a numerous host of techniques such as chi-square, gini coefficient, entropy,
etc. The other techniques unfortunately could not differentiate components as well
as the t-test. For instance, in using the chi-square test, some of the minimal values
required for the parameters of the chi-square test are often not fulfilled. Entropy
failed as a metric as well because the (absolute) value of the entropy is high when the
components behave similarly across phenotypes (a case of total information) as well as
when the components behave totally differently across phenotypes (a case of totally no
information). Ultimately, we found the t-test to still be the best in capturing the different
behaviour of components across different phenotypes.
8.3.4 Size of Subnetwork
In the beginning of the project we had attempted to carry out our pathway analysis on
a smaller scale (using only < 5 pathways) using an extremely manual process. Although
such a technique would provide us with results of a very high granularity, reproducing
such techniques on the many pathways available would not have been a feasible option.
In addition, it would run contrary to the technological trend that requires us to process
more data within a shorter period of time. After the decision was made to expand the
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analysis to a technique that is scalable, we managed to test our algorithm in rapidly
across many pathways.
8.3.5 Overlap of Components vs Overlap of Genes
We recognise that the percentage overlap of components is consistently not as high as
compared to the overlap of genes. We argue that such a phenomena occurs because there
is a key group of genes (which belong to a few key components) acting specifically for that
phenotype. However this key group of genes (being more influential) occur in various
other (non significant) components as well. Hence when spurious genes or false positives
(possibly due to batch effect) occur, they may make the non-significant components to be
deemed as significant as well. This probably means that the technique is still not refined
enough to capture the nuances within the components since it is unable to reject such
false positives.
8.3.6 Selection of m and n
We have chosen the value of m and n through empirical means and found 10% of the
top genes, 50% of patients as suitable parameters to be used in the experiment. A more
methodological way is to assess based on the distribution of gene expression values.
Specifically, we can:
1. Optionally perform a log transform of the gene expression values.
2. Divide the gene expression values into 100 intervals (buckets).
3. (iii) Plot the frequency distribution of gene expression values into these intervals
to provide a normal distribution.
4. Most of the samples (in our experience, 8˜0%) will be near the mean, x˜% (in our
experience, 1˜0%) near the left (i.e. low) extreme. x˜% (in our experience, 1˜0%) near
the right (i.e. high) extreme. This suggests x% to be the threshold.
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It is also possible to consider an optimization approach, first seeding the values of n
and m, and then carry out a simple hill climbing process, tweaking the values of n and
m and stopping when the score starts to deteriorate (this score can be the number of
consistent subneworks obtained). The seeding of n and m with the hill climbing can be
repeated several times to ensure that we do not hit into a local maximum. However, this
approach may risk overtuning of the n and m parameters.
8.3.7 Extension to other datasets
As mentioned in the previous section, one of the extensions would be to create a large-
scale tool which will be able to read both microarray data and biological data presented
in different formats. This is a non-trivial engineering issue and a possible solution will
be to standardize two fixed formats. One format for the microarray data and the other for
the biological data. Software connectors will be written to convert both the microarray
data as well as the biological data into one of these fixed formats. The algorithm then
accepts only these two fixed formats as inputs. This framework will allow other formats
to be easily added and make the tool more scalable.
8.3.8 Specificity of the Algorithm
When running the algorithm for the leukemia dataset, we failed initially to take note
that the data consisted of different types of ALL leukemia. Although both datasets
boasted that the samples were taken from ALL patients, we were unaware that
(Armstrong et al., 2002) consisted of patients only from T-cell ALL patients while the
dataset from (Golub et al., 1999) consisted of patients from B-cell ALL and T-cell ALL. In
using the mixed dataset, we were unable to find a good component intersection between
the datasets and the percentage overlap stuck at 30% or lower. However when this
was discovered and we removed the B cell patients from the list, the overlap percentage
increased to more than 70%. This shows the high level of specificity of the algorithm.
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APPENDIX A
Histograms
We show here the histograms from the connected components in Chapter 7.
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Figure A.1: Histogram of leukemia connected components (a).
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Figure A.2: Histogram of leukemia connected components (b).
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Figure A.3: Histogram of leukemia connected components (c).
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Figure A.4: Histogram of leukemia connected components (d).
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Figure A.5: Histogram of leukemia connected components (e).
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Figure A.6: Histogram of leukemia connected components (f).
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Figure A.7: Histogram of leukemia connected components (g).
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Figure A.8: Histogram of DMD connected components (a).
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Figure A.9: Histogram of DMD connected components (b).
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Figure A.10: Histogram of DMD connected components (c).
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Figure A.11: Histogram of Subtype connected components (a).
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Figure A.12: Histogram of Subtype connected components (b).
Appendix A. Histograms 154
Figure A.13: Histogram of Subtype connected components (c).
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Figure A.14: Histogram of Subtype connected components (d).
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Figure A.15: Histogram of Lung connected components (a).
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Figure A.16: Histogram of Lung connected components (b).
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Figure A.17: Histogram of Lung connected components (c).
Figure A.18: Histogram of Lung connected components (d).
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